


Cell Host & Microbe

NLRP12 Regulates Anti-viral RIG-I Activation via Interaction with TRIM25

Graphical Abstract



Authors

Szu-Ting Chen, Liang Chen, Diego Shih-Chieh Lin, ..., Hye-Ri Kang, Jae U. Jung, Jenny P.-Y. Ting

Correspondence

chensztin@ym.edu.tw (S.-T.C.), jenny_ting@med.unc.edu (J.P.-Y.T.)

In Brief

Chen et al. show that the nucleotide-binding domain and leucine repeat domain-containing protein NLRP12 associates with the ubiquitin ligase TRIM25 to reduce K63-linked ubiquitination of the anti-viral innate immune receptor RIG-I. This prevents RIG-I association with MAVS and thus serves as a checkpoint for interferon and cytokine induction in response to RNA viruses.

Highlights

- NLRP12 reduces interferon and cytokine responses to RNA viruses and 5'ppp-dsRNA
- NLRP12 associates with TRIM25 to disrupt Lys63 ubiquitination and activation of RIG-I
- Vesicular stomatitis virus (VSV) infection downregulates NLRP12
- Myeloid-specific *Nlrp12*-deficient mice have increased resistance to VSV

NLRP12 Regulates Anti-viral RIG-I Activation via Interaction with TRIM25

Szu-Ting Chen,^{1,2,3,*} Liang Chen,^{3,4} Diego Shih-Chieh Lin,⁵ Sei-Yi Chen,^{6,7} Yen-Po Tsao,^{1,8} Haitao Guo,^{3,9} Fei-Ju Li,¹ Wei-Ting Tseng,¹ Jason W. Tam,^{3,9} Chih-Wei Chao,¹ W. June Brickey,^{3,4} Ivan Dzhagalov,¹⁰ Moon-Jung Song,^{3,11} Hye-Ri Kang,^{3,11} Jae U. Jung,¹² and Jenny P.-Y. Ting^{3,4,9,13,14,*}

¹Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan

²Cancer Progression Research Center, National Yang-Ming University, Taipei, Taiwan

³Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA

⁴Department of Microbiology and Immunology, University of North Carolina, Chapel Hill, NC, USA

⁵Department of Pathology and Laboratory Medicine, Taipei Veterans General Hospital, Taipei, Taiwan

⁶Department of Neurosurgery, Chung-Shan Medical University Hospital, Taichung, Taiwan

⁷School of Medicine, Chung-Shan Medical University, Taichung, Taiwan

⁸Division of Allergy, Immunology, and Rheumatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan

⁹Department of Genetics, University of North Carolina, Chapel Hill, NC, USA

¹⁰Department of Microbiology and Immunology, National Yang-Ming University, Taipei, Taiwan

¹¹Virus-Host Interactions Laboratory, Department of Biosystems and Biotechnology, Division of Biotechnology, College of Life Sciences and Biotechnology, Korea University, Seoul, Republic of Korea

¹²Department of Molecular Microbiology & Immunology, University of Southern California Keck School of Medicine, CA, USA

¹³Institute of Inflammatory Diseases, Center for Translational Immunology, University of North Carolina, Chapel Hill, NC, USA

¹⁴Lead Contact

*Correspondence: chensztin@ym.edu.tw (S.-T.C.), jenny_ting@med.unc.edu (J.P.-Y.T.)

<https://doi.org/10.1016/j.chom.2019.02.013>

SUMMARY

Establishing the balance between positive and negative innate immune mechanisms is crucial for maintaining homeostasis. Here we uncover the regulatory crosstalk between two previously unlinked innate immune receptor families: RIG-I, an anti-viral cytosolic receptor activated type I interferon production, and NLR (nucleotide-binding domain, leucine repeat domain-containing protein). We show that NLRP12 dampens RIG-I-mediated immune signaling against RNA viruses by controlling RIG-I's association with its adaptor MAVS. The nucleotide-binding domain of NLRP12 interacts with the ubiquitin ligase TRIM25 to prevent TRIM25-mediated, Lys63-linked ubiquitination and activation of RIG-I. NLRP12 also enhances RNF125-mediated, Lys48-linked degradative ubiquitination of RIG-I. Vesicular stomatitis virus (VSV) infection downregulates NLRP12 expression to allow RIG-I activation. Myeloid-cell-specific *Nlrp12*-deficient mice display a heightened interferon and TNF response and are more resistant to VSV infection. These results indicate that NLRP12 functions as a checkpoint for anti-viral RIG-I activation.

INTRODUCTION

NLR (nucleotide-binding oligomerization domain and leucine-rich repeat-containing protein, also known as NOD-like receptor) proteins have garnered attention as a large family of intracellular pattern recognition receptors and/or sensors. These proteins

trigger inflammation in response to pathogen infection and sterile activators including self (host)- and environment-derived molecules (Davis et al., 2011). This function is illustrated by a number of NLR proteins that display inflammasome function. Inflammasome NLRs such as NLRP1, NLRP3, NLRC4, and NLRP6 assemble with ASC (apoptotic speck-containing protein with CARD) and procaspase 1 to form an inflammasome complex leading to caspase 1 activation to cause the maturation and subsequent release of mature IL-1 β and IL-18 (Broz and Dixit, 2016). However, NLRs also have functions that are independent of the inflammasome. The most prominent examples are CIITA and NLRC5, which respectively act as master transcriptional activators that regulate class II and I major histocompatibility complex (MHC) gene expression (Kufer and Sansonetti, 2011; Ting et al., 2010). Most relevant to this work, several NLR proteins have been found to act as negative regulators of crucial innate immune pathways, including the canonical and non-canonical nuclear factor κ B (NF- κ B), mitogen-activated protein kinase (MAPK), cytokine production, and type I interferon (IFN-I) pathways (Allen et al., 2012; Cui et al., 2012; Moore et al., 2008; Wang et al., 2015).

NLRP12 (NLR family pyrin domain containing 12) is a pyrin-containing NLR protein primarily expressed by dendritic cells (DCs) and neutrophils with a low to undetectable expression level in macrophages (Arthur et al., 2010; Vladimer et al., 2012; Zaki et al., 2011). In an overexpression system, NLRP12 is co-localized with the inflammasome adaptor ASC, leading to caspase 1 activation (Wang et al., 2002). In *Nlrp12*^{-/-} cells, the protein is implicated in inflammasome function in response to *Yersinia* (Vladimer et al., 2012) and malaria (Ataide et al., 2014). However, deletion or reduction of *Nlrp12* is correlated with increased IL-1 β plus other cytokines during obesity (Truax et al., 2018). This implies that its inflammasome-inducing function may be restricted to specific stimuli, while the protein also may negatively regulate inflammasome- and non-inflammasome-associated

cytokine production (Papale et al., 2017; Silveira et al., 2017; Zaki et al., 2014). Its negative regulatory functions are exerted through the suppression of non-canonical NF- κ B activation by associating with NF- κ B-inducing kinase (NIK) to promote NIK degradation in a proteasome-dependent pathway (Lich et al., 2007). In a colitis-associated colorectal cancer model and osteoclast differentiation, *Nlrp12*^{-/-} mice show exaggerated non-canonical and canonical NF- κ B activation in addition to ERK phosphorylation (Allen et al., 2012; Krauss et al., 2015; Zaki et al., 2011). *Nlrp12*^{-/-} mice also exhibit enhanced disease in a mouse model of multiple sclerosis (Gharagozloo et al., 2015; Lukens et al., 2015) and enhanced inflammatory response to *Salmonella* and *Brucella* (Silveira et al., 2017; Zaki et al., 2014). Finally, it is required for neutrophil and dendritic cell migration to an inflammatory site (Arthur et al., 2010; Cai et al., 2016; Ulland et al., 2016), primarily through the regulation of CXCL1 (Hornick et al., 2018), although one study found the opposite in culture (Zamoshnikova et al., 2016). Recently, NLRP12 has been reported to regulate gut microbiota, favoring commensal bacteria that suppress colitis and metabolic diseases (Chen et al., 2017; Truax et al., 2018). While the roles of NLRP12 in sterile inflammation and bacterial infection have been investigated, the biological role of NLRP12 in host immune response against virus infection is less studied. A recent study by Hornick et al. (2018) demonstrated a detrimental role for NLRP12 in influenza infections through excessive neutrophil recruitment. The present report shows that, in a different route of infection with a different virus, NLRP12 serves as a checkpoint against anti-viral immunity, specifically by blocking IFN-I production through its impact on ubiquitin ligases. Checkpoint proteins are found in multiple biologic processes, with the earliest examples described during cell cycle regulation (Hartwell and Weinert, 1989). Our report shows that NLRP12-mediated function is achieved by interference with the E3 ligase TRIM25 (Gack et al., 2007), which is required for the Lys63-linked polyubiquitin-activation of retinoic-acid-inducible gene I (RIG-I), a cytosolic pattern recognition receptor for viral RNA (Yoneyama et al., 2004). Oligomerized RIG-I interacts with and activates the mitochondria antiviral signaling adaptor MAVS (VISA, IPS-1 or Cardif) (Tan et al., 2018), which then associates with adaptor proteins to recruit TRAF3 and TRAF family-member-associated NF- κ B activator (TANK) and trigger the activation of TANK binding kinase-1 (TBK1) and the I κ B kinase (IKK-epsilon); this leads to activated IRFs (Mao et al., 2010; Saha et al., 2006; Seth et al., 2005) and IFN (Kawai et al., 2005). During the resolution phase of viral infection, RIG-I signaling is degraded after conjugation of Lys48 ubiquitin by the ring-finger protein 125 (RNF125) (Arimoto et al., 2007). This report shows that *Nlrp12* deficiency in myeloid cells leads to increased immune signaling to RNA viruses and 5' triphosphate double-stranded RNA by affecting TRIM25 and RNF125 to alter RIG-I activation and degradation.

RESULTS

Nlrp12 Deletion in Bone-Marrow-Derived DCs Enhances IFN-I Induction by an RNA Virus and Double-Stranded RNA

We investigated the function of NLRP12 during a viral infection. The human *NLRP12* gene is abundantly expressed by CD14⁺-

derived macrophages, DCs, and neutrophils, while mouse *Nlrp12* is more highly expressed by DCs (Arthur et al., 2010). *Nlrp12* is lowly expressed in mouse bone-marrow-derived macrophages (BMDMs) and negligible in mouse embryonic fibroblasts (MEFs) when compared to its expression in DCs (Figure 1A); thus, we focused on its role in DCs. We infected bone-marrow-derived dendritic cells (BMDCs) with vesicular stomatitis virus (VSV), a negative single-strand RNA virus ([−] ssRNA) and measured cytokine production by ELISA. Significantly higher amounts of TNF (Figure 1B), IFN- β (Figure 1C), *Irfn*, and *Irfn4* transcripts (Figures 1D and 1E) were observed in *Nlrp12*^{-/-} DCs than in WT DCs after VSV infection of different multiplicities of infection (MOI) and times after infection.

Non-self ligands or PAMPs of viruses, including uncapped 5' triphosphate containing short double-stranded RNA (5'ppp-dsRNA) and short double-stranded RNA polymers polyinosinic-polycytidylic acid [poly(I:C)], are recognized by RIG-I (Hornung et al., 2006; Pichlmair et al., 2006; Yoneyama et al., 2004). Significantly higher amounts of IFN- β protein and *Irfn* and *Irfn4* transcripts were detected in *Nlrp12*^{-/-} DCs compared to WT DCs after transfection of 5'ppp-dsRNA or low-molecular-weight (LMW) poly(I:C) (Figures 1F–1K). Poly(I:C) can be recognized by both RIG-I and TLR3; however, 5'ppp-dsRNA is only recognized by RIG-I (Lu et al., 2010). These findings suggest that NLRP12 negatively regulates IFN- β stimulated by a RIG-I ligand. During viral infection, viral titers (Figure 1L) and relative viral genomic copy numbers (Figure 1M) were significantly reduced in *Nlrp12*^{-/-} DCs at different times and MOIs compared to WT DCs. The inhibitory effect of NLRP12 was most prominently observed at lower MOIs (0.05 and 0.5) compared to a higher MOI (5.0), suggesting that there may be a threshold at which NLRP12 can no longer attenuate an anti-viral response. In addition to the *Nlrp12*^{-/-} strain that has been previously reported (Allen et al., 2012; Zaki et al., 2011), a second *Nlrp12*^{-/-} strain referred to as *Nlrp12*^{-/-#2} was generated using CRISPR/Cas in Taiwan in the C57BL/6J background (Figures S1A–S1D and STAR Methods) and produced a similar outcome (Figures S1E and S1F).

NLRP12 Inhibits the RIG-I-Dependent Pathway

Since 5'ppp-dsRNA activates RIG-I, we investigated whether NLRP12 affects RIG-I function. Overexpression of NLRP12 in HEK293 cells attenuated the activation of IFN- β promoter luciferase reporter activity by RIG-I, TRIM25, and MAVS in a dose-dependent manner, but not by STING (stimulator of interferon genes), a receptor of cyclic dinucleotides produced after DNA binding to cyclic GAMP synthase (cGAS) (Figure 2A). NLRP12 overexpression also inhibited the activation of the interferon-stimulated responsive element (ISRE) promoter by RIG-I and MAVS, but not by STING (Figure 2B). NLRP12 significantly suppressed the NF- κ B promoter activated by RIG-I and MAVS, but not by TRAF3 (Figure 2C). Finally, NLRP12 reduced RIG-I-dependent IFN- β promoter-driven luciferase activity induced by 5'ppp-dsRNA or poly(I:C) (Figure 2D). These results suggest that a major effect of NLRP12 is the inhibition of RIG-I-mediated signaling.

Nlrp12^{-/-} DCs Exhibit Elevated Immune Signaling after VSV Infection and 5'ppp-dsRNA Stimulation

To assess changes in RIG-I-mediated signaling cascades upon viral infection, we analyzed changes in the phosphorylation of




Figure 1. NLRP12 Suppresses VSV and Short dsRNA-Induced Production of IFN-I

(A) RNAs were harvested from bone-marrow-derived dendritic cells (BMDCs), bone-marrow-derived macrophages (BMDMs), and mouse embryonic fibroblasts (MEFs) and assayed for *Nlrp12* mRNA expression. *Nlrp12* expression level in BMDCs was denoted as 100%, and the relative *Nlrp12* expression in BMDMs and MEFs was compared to that expressed by BMDCs. BMDCs from wild-type (WT) and *Nlrp12*^{-/-} mice were infected with VSV (MOI 0.05 and 0.5). (B–E) Supernatants and cell lysates were measured for (B) TNF, (C) IFN-β protein, (D) *Ifnb* and (E) *Ifna4* transcripts by ELISA and real time qPCR, respectively. (F–K) WT and *Nlrp12*^{-/-} BMDCs were transfected with (F, G, and H) 5'ppp-dsRNA or (I, J, and K) low molecular weight (LMW) poly(I:C). (L and M) BMDCs were infected with VSV (MOI 0.5), with (L) virus titer and (M) relative amount of VSV genomic RNA determined by plaque assay and real time qPCR, respectively.

WT level at each MOI and time point was set to 100%, and levels in *Nlrp12*^{-/-} cells were compared to these values. Representative data were collected and expressed as mean ± SEM from at least three independent experiments. Student's t test was performed, with *p < 0.05 or **p < 0.01 for WT versus *Nlrp12*^{-/-} mice.




Figure 2. NLRP12 Suppresses RIG-I-Mediated IFN- β , ISRE, and NF- κ B Reporter Activities

(A–C) HEK293 cells were transfected with 100 ng of (A) IFN- β , (B) ISRE, or (C) NF- κ B luciferase reporter with the internal control Renilla luciferase reporter pLR-TK plasmid and indicated plasmids (RIG-I, TRIM25, MAVS, STING, or TRAF3) in the presence of empty vector (EV, pCDNA3) or NLRP12-encoding plasmid (pCDNA3/HA-NLRP12, 30, 100, 300 ng/sample). Luciferase assays were performed 24 h post-transfection.

(D) HEK293 cells were transfected with IFN- β luciferase reporter (30 ng), pLR-TK (3ng), and pFlag-CMV2-RIG-I plasmid (300 ng) or pFlag-CMV2 (Vector) with EV or NLRP12 expression plasmid (300 ng). 5' ppp-dsRNA and LMW poly(I:C) were then transfected into these cells at 24 h, and luciferase assays were performed 12 h later.

Data were collected and expressed as mean $\pm$ SEM from at least three independent experiments. Student's t test was performed, * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$ for EV versus NLRP12 transfectants.

effectors that lie downstream of RIG-I. Phosphorylated TBK1 (pTBK1) and IRF3 (pIRF3) were induced 2 to 8 h after VSV infection in WT DCs, while these signals were significantly higher in *Nlrp12*^{−/−} DCs (Figure 3A). A compilation of results from three experiments is shown (Figure 3A, bottom). NF- κ B lies downstream of the RIG-I signaling cascade and is a key transcriptional factor for IFN and proinflammatory cytokine genes. Phosphorylated NF- κ B p65 (p-p65) was induced 2 to 8 h after VSV infection in WT cells and was enhanced significantly in *Nlrp12*^{−/−} DCs (Figure 3A). VSV did not induce the processing

of p100 into p52 in WT cells, but *Nlrp12*^{−/−} DCs exhibited constitutive non-canonical NF- κ B activation without VSV stimulation (Figure 3A). We also used microscopy to analyze p65 nuclear translocation. At 4 h post-infection, 3% of p65 nuclear translocation was detected in WT and *Nlrp12*^{−/−} DCs, while this number was increased to 5%–7% and 38%, respectively, by 8 and 18 h after VSV infection in WT cells and to 11% and 65% in *Nlrp12*^{−/−} DCs at these two time points (Figure 3B). As expected, the microscopic changes of nuclear translocation lagged behind p-p65 in Figure 3A.




Figure 3. *Nlrp12* Deficiency Promotes Innate Immune Signaling

(A) WT and *Nlrp12*^{-/-} BMDCs were infected with VSV (MOI 0.5), and cell lysates were harvested and assayed for pTBK1, pIRF3, NF- κ B p-, and non-canonical NF- κ B processing of p100 to p52. For the densitometric analysis throughout this figure, bands were normalized with individual GAPDH, and % phosphorylated protein over total amount of that protein was determined from at least three experiments, expressed as mean $\pm$ SEM and analyzed by Student's t test. *p < 0.05 for WT versus *Nlrp12*^{-/-} cells.

(legend continued on next page)

We next investigated the impact of NLRP12 on immune signaling caused by the RIG-I ligand 5'ppp-dsRNA. pTBK1 was slightly induced at 4 h following 5'ppp-dsRNA transfection and peaked at 8 h post-transfection in WT DCs, whereas pTBK1 was significantly higher in *Nlrp12*^{-/-} DCs at 4 h and sustained through 8 h post-transfection (Figure 3C). pIRF3 was modestly induced in WT cells 4 to 8 h post-transfection with 5'ppp-dsRNA, while the signal was significantly augmented in *Nlrp12*^{-/-} DCs 4 h post transfection (Figure 3C, right is composite data). Studies described in Figures 3A–3C were also performed in *Nlrp12*^{-/-#2} with similar outcomes (Figure S1G). To validate these data in humans, we transfected human monocyte-derived DCs (moDCs) with pooled NLRP12 siRNA, and the efficacy of knockdown was confirmed by immunoblot (Figure 3D). NLRP12 siRNA resulted in increased IFN- α secretion (Figure 3E) and enhanced pIRF3 (Figure 3F, right is composite data) after VSV infection, indicating that human NLRP12 also reduced an IFN response.

NLRP12 Interacts with TRIM25 to Interfere with RIG-I-Mediated Signaling Cascade

To explore the mechanism by which NLRP12 reduced the RIG-I-mediated signaling cascade, we tested whether NLRP12 physically interacted with key adaptor proteins in the RIG-I signaling pathway including RIG-I, TRIM25, TBK1, TRAF3, TRAF6, and IKK α by co-immunoprecipitation with NLRP12. Endogenous TRIM25 but not others interacted with overexpressed NLRP12 protein, but this association was reduced by VSV (Figures S2A and S2B). In addition, overexpressed TRIM25 interacted with overexpressed NLRP12, but not with the negative control NLRX1 (Moore et al., 2008) (Figure 4A). Domain mapping analysis indicated that protein derived from constructs expressing full-length NLRP12, pyrin-NBD, NBD, and NBD-LRR associated with endogenous TRIM25, whereas the pyrin or LRR domain of NLRP12 did not (Figure 4B). Thus, NBD alone or combined with either pyrin or LRR can interact with TRIM25, while pyrin or LRR alone cannot.

We next tested the functional effects of these deletion constructs. Truncated NLRP12 mutants with pyrin-NBD, NBD, and NBD-LRR domains suppressed the IFN- β promoter luciferase activity induced by RIG-I and TRIM25 as efficiently as full-length NLRP12 (Figure 4C), while pyrin and LRR alone had no effect. This indicates that the NBD domain is needed for the suppression of RIG-I-mediated IFN- β expression. NLRP12 interacted with TRIM25 at the basal level, but this interaction was gradually diminished upon VSV infection, suggesting that viral infection relieved TRIM25 from this inhibitory NLR (Figure 4D). Another E3 ligase, RING-finger protein (RNF125), causes the degradation of ubiquitin-conjugated RIG-I in a proteasome-dependent manner, but it did not associate with NLRP12 (Figure 4D).

Interestingly, the level of endogenous NLRP12 in human DCs was gradually reduced after a VSV infection. NLRP12 mRNA (Figure S2C) and protein (Figure 4E) were both reduced from 2–8 hours post-infection. Similarly, murine *Nlrp12* mRNA was reduced by VSV infection (Figure S2D). We then assessed human NLRP12 protein expression in DCs due to the availability of a good commercial antibody for human but not mouse NLRP12 protein. In an immunofluorescence assay, NLRP12 protein was abundantly expressed in human DCs, but the expression level was gradually diminished over time (2–8 hpi) following VSV infection (Figure 4F). NLRP12 was not located at the mitochondria at resting state, nor was its localization altered by VSV infection (Figure 4F). These results indicate that NLRP12 attenuates the RIG-I pathway by targeting TRIM25, while viral infection reduces NLRP12 expression, thus providing one mechanism to remove its blockade of RIG-I function.

NLRP12 Reduces Lysine 63-Linked but Enhances Lysine 48-Linked Ubiquitination of RIG-I

Lysine 48 (Lys48)-linked polyubiquitin chains target proteins for destruction in a proteasome-dependent process, while Lysine 63 (Lys63)-linked polyubiquitin chains are considered activation modifications not associated with proteasomal degradation. TRIM25 interaction with RIG-I leads to Lys63-linked, activation ubiquitination of RIG-I (Gack et al., 2007) which increases RIG-I-MAVS interaction, RIG-I tetramerization, stabilization, and subsequent signaling transduction (Peisley et al., 2014).

TRIM25 associated with RIG-I as reported, but NLRP12 reduced both this association (Figure 5A) and TRIM25-mediated Lys63-linked ubiquitination of RIG-I (Figure 5B). In contrast, RNF125-mediated Lys48-linked ubiquitination of RIG-I was increased by NLRP12 (Figure 5C). This suggests that NLRP12 reduces TRIM25-mediated Lys63-linked activation ubiquitination while enhancing RNF125-mediated Lys48-linked degradative ubiquitination of RIG-I.

As these experiments involved an overexpression system, we next investigated these same pathways in *Nlrp12*^{-/-} cells. WT DCs exhibited increased Lys63-linked ubiquitin on RIG-I, with maximal ubiquitination detected by 4–8 h after VSV infection, while *Nlrp12*^{-/-} cells showed even greater Lys63-linked ubiquitination of RIG-I at these time points (Figure 5D). Conversely, Lys48-linked degradative ubiquitin on RIG-I was enhanced at 8 h after VSV infection in WT DCs, while *Nlrp12*^{-/-} cells did not exhibit this enhancement (Figure 5D). Consistent with these findings, RIG-I gradually increased over time after VSV infection in WT cells. In *Nlrp12*^{-/-} cells, a higher basal level (0 h) was observed, and a further increase of RIG-I protein was detected post-infection (4–8 h, Figure 5E). Studies described in Figures 5D and 5E were also performed in *Nlrp12*^{-/-#2} with similar outcomes (Figures S2E and S2F). Enhanced Lys63-linked ubiquitination of RIG-I and

(B) WT and *Nlrp12*^{-/-} BMDCs were infected with VSV (MOI 0.5); stained with antibody to NF- κ B p65 (red), DAPI (blue, nucleus), and Alexa Fluor-488 Phalloidin (green, cytoplasm); and visualized by confocal microscopy; scale bar 20 μ m. Arrowhead: representative p65 nuclear translocation (pink). Right, quantification of nuclear p65 from five fields (30 cells per field) collected from three experiments; and Student's t test shows * $p < 0.05$ for WT versus *Nlrp12*^{-/-} cells.

(C) WT and *Nlrp12*^{-/-} BMDCs were transfected with 5'ppp-dsRNA, and cell lysates were analyzed for pTBK1 and pIRF3. Graphs to the right, * $p < 0.05$ for WT versus *Nlrp12*^{-/-} cells.

(D) Human DCs (moDCs) were transfected with NLRP12 siRNA or scrambled siRNA (nonspecific, NS) for 48 h and validated for reduced NLRP12 expression.

(E) Cells were infected with 1 MOI of VSV and assayed for IFN- α by ELISA.

(F) VSV-infected cells were harvested for immunoblotting. A representative blot from three is shown. Densitometry of pIRF3 (right) with * $p < 0.05$; ** $p < 0.01$.




Figure 4. NLRP12 NBD Domain Interacts with TRIM25 to Reduce RIG-I-TRIM25 Association

(A) HEK293 cells were transfected with plasmids as indicated, and immunoprecipitation (IP) was followed by immunoblotting (IB) with the indicated antibodies 24 h after transfection.

(B) HEK293 cells were transfected with domain-deletion constructs of NLRP12 and co-immunoprecipitation with endogenous TRIM25 24 h later.

(C) HEK293 cells were transfected with 100 ng of IFN- β luciferase reporter with pLR-TK and indicated plasmids (RIG-I or TRIM25) in the presence of empty vector (EV, pCDNA3-V5) or domain constructs of NLRP12. Luciferase assays were performed 24 h post transfection.

(D) HEK293 cells were infected with VSV (MOI 1) following transfection of the HA-NLRP12 plasmid. Endogenous TRIM25 and RNF125 were pulled down with anti-TRIM25 and anti-RNF125 antibodies respectively and immunoblotted with anti-HA for associated NLRP12.

(E) Human DCs were infected with VSV (MOI 1) and subjected to immunoblotting for endogenous NLRP12 protein. Densitometry indicates that the protein level went from 100% (mock) to 43% (2-h time point), 38% (4 h) and 26% (8 h).

(F) Confocal microscopic images of VSV-infected human DC, endogenous NLRP12 (red), mito-tracker (green), and DAPI (blue). Scale bar, 10 μ m.




Figure 5. NLRP12 Reduces Lys63-Linked but Enhances Lys48-Linked Ubiquitination of RIG-I

(A–C) HEK293 cells were transfected with plasmids as indicated, and co-immunoprecipitation was performed 24 h post transfection. Right sides and all graphical data in this figure are composite densitometry from three experiments expressed as mean $\pm$ SEM. (A) Right graph, densitometry of TRIM25-RIG-I interactions. (B) and (C) right graphs, densitometry of K63-Ub and K48-Ub signal on RIG-I, respectively. RIG-I ubiquitination signal was normalized to total RIG-I levels. The relative fold change is shown in the histogram. Student's t test was performed. * is $p < 0.05$.

(D) WT and *Nlrp12*^{-/-} BMDCs were infected with VSV (MOI 0.5), and cell lysates were subjected to immunoprecipitation with antibody against RIG-I. Levels of Lys63-linked (upper) and Lys48-linked ubiquitin (lower) on RIG-I were measured by immunoblotting with antibodies against K63-Ub or K48-Ub. RIG-I ubiquitination signals were normalized to GAPDH, and the basal RIG-I ubiquitination signal for WT group at 0 h was set as "1." Relative fold change is shown in graphic form.

(E) VSV-infected WT and *Nlrp12*^{-/-} BMDCs were harvested and immunoblotted for RIG-I levels. Densitometry of RIG-I expression was measured as described in (D).

(F) VSV-infected WT and *Nlrp12*^{-/-} BMDC lysates were immunoprecipitated with antibody against MAVS. RIG-I-MAVS interactions and MAVS levels were measured by immunoblot. The densitometry of RIG-I-MAVS interactions and MAVS expression was measured as described in (D) and expressed in graphic form below each immunoblot.

increased RIG-I protein in *Nlrp12*^{-/-} cells are predicted to promote RIG-I interaction with MAVS. Indeed, earlier and longer-lasting RIG-I-MAVS interaction was observed in *Nlrp12*^{-/-} cells (Figure 5F). In contrast to the reduction of RIG-I by the presence of NLRP12 (Figure 5E), NLRP12 did not affect MAVS protein levels (Figure 5F).

Nlrp12 Deficiency Augments Host Response to VSV Infection

We next examined the *in vivo* impact of NLRP12. A preliminary experiment was performed in the *Nlrp12*^{-/-} strain to show that this strain had increased IFN and lower viral load; however, due to the difficulty of obtaining proper material transfer documents, *Nlrp12*^{-/-#2} mice were later generated in Taiwan for additional *in vivo* studies. Intranasal (i.n.) infection with VSV triggers type I IFN in the central nervous system and periphery of mice, and this response is critical for viral control (Detje et al., 2015). Serum and cerebral spinal fluid (CSF) levels of IFN- β (Figures 6A and 6B) as well as *Ifnb* and *ifna4* transcripts (Figures 6C and 6D) were

significantly higher in *Nlrp12*^{-/-#2} mice at 24 h after VSV infection than in WT controls. Relative brain VSV genomic RNA expression (Figure 6E), viral titers (Figure 6F), and viremia (Figure 6G) were significantly reduced in *Nlrp12*^{-/-#2} mice.

To assess the impact of NLRP12 in brain DCs, we isolated brain mononuclear cells (MNCs) from VSV-infected WT and *Nlrp12*^{-/-#2} mice 12 h post-infection. DCs (CD11b⁺CD11c⁺) constituted approximately 2.4% of total brain MNC in WT and *Nlrp12*^{-/-#2} mice (Figure S3A). *Nlrp12*^{-/-#2} DCs from VSV-infected brain tissues expressed significantly higher IFN- α (mean fluorescence intensity [MFI]: 2,508) than the WT DCs (MFI: 1,114) (Figure 6H), and the same was observed with TNF (MFI 10,210 versus 6,590) (Figure 6I). *Nlrp12*^{-/-#2} brain DCs (Figure S3B) and macrophages (Figure S3C) as well as splenic DCs (Figure S3D) and macrophages (Figure S3E) also had higher RIG-I expression than WT counterparts. These data demonstrate that *Nlrp12* deletion results in greater type I IFN production and RIG-I protein.

In concert with these observations, some of the WT mice presented with dyskinesia and significant lethargy following VSV infection (Video S1), whereas *Nlrp12*^{-/-#2} mice were energetic (Video S2). WT mice showed noticeable weight loss starting from day 2 post-infection, with all subjects exhibiting significantly more weight loss than *Nlrp12*^{-/-#2} mice from days 5 to




Figure 6. *Nlrp12*^{-/-} Mice are More Resistant to VSV Infection

(A and B) WT and *Nlrp12*^{-/-} mice were inoculated with VSV (1×10^6 PFU) intranasally. (A) Serum and (B) cerebral spinal fluid (CSF) were assayed for IFN-β by ELISA 24 h post-infection.

(C and D) Brain *Ifna4* (C) and *Ifnb* (D) transcripts were measured by real-time qPCR.

(E) Brain-localized VSV genomic RNA was determined by qPCR.

(F and G) Viral titers in (F) brain and (G) serum were determined by plaque assays.

(legend continued on next page)

14 post-infection (Figure 6J) and one-fifth of the infected WT mice died between days 5 and 6 (Figure 6J, arrow). In contrast, *Nlrp12*^{-/-#2} mice lost only 3% of their body weight during the first 3 days following infection and showed full recovery (100% or more) by day 6. Pathology examination showed rare healthy neurons and marked neuronal loss in the ventral striatum and hypothalamus of VSV-infected WT mice compared to uninfected mice (Figure 6K). By contrast, VSV infected *Nlrp12*^{-/-#2} mice showed significantly milder neuronal loss. Reactive astrocytes (Figure 6L, brown immunoperoxidase staining) indicative of enhanced expression of a reactive astrocytic biomarker, glial fibrillary acidic protein (GFAP), was found in WT but reduced in *Nlrp12*^{-/-#2} mice (Figure 6L). Increased astrogliosis typically accompanies CNS insult in VSV-infected WT mice (Sofroniew and Vinters, 2010). Taken together, *Nlrp12*^{-/-#2} mice, showed enhanced host response against VSV and had less neuron loss and astrogliosis than WT controls following VSV infection.

We next investigated if *Nlrp12* deficiency altered immune infiltration in brain tissue during VSV infection. Lymphocyte infiltration was observed in both WT and *Nlrp12*^{-/-#2} brain tissue during VSV infection (Figure 6K, blue arrows). Brain mononuclear cells were isolated and analyzed. At day 5 post-infection, about 0.1% of cells express myeloid DC markers (CD11b⁺CD11c⁺) (Figure S4A). Among these, monocytes (CD11b⁺Ly6C^{hi}) represented approximately 20%–21% of the CD11b⁺ (Figure S4B), and neutrophils (CD11b⁺Ly6G⁺) were negligible (Figure S4B). CD3⁺ T cells were the most abundant immune cells (Figure S4C). The proportions of myeloid cells, monocytes, CD3⁺ T cells, and CD4⁺/CD8⁺ T cells in brain tissue were similar in WT and *Nlrp12*^{-/-#2} mice.

Because *Nlrp12* was reported to be expressed by mouse CD4⁺ and CD8⁺ T cells (Lukens et al., 2015), we investigated the T cell intrinsic role of NLRP12 during VSV infection at an early and late time points. At day 3 (Figure S5) and day 9 (Figure S6) post-infection, the proportion of CD3⁺, CD4⁺, or CD8⁺ T cells from WT and *Nlrp12*^{-/-#2} was similar in the brain (Figures S5A and S6A) and the submandibular draining lymph node (SLN) (Figures S5B and S6B). By day 3 and day 9 post-infection, WT and *Nlrp12*^{-/-#2} CD4⁺ and CD8⁺ T cells expressed a similar level of IFN- γ protein in the brain tissue (Figures S5C, S5D, and S6C–S6D) and SLN (Figures S5E, S5F, and S6E–S6F). These results suggest that NLRP12 did not affect T cells derived from IFN- γ production during VSV infection.

To determine if NLRP12 has a T-cell-intrinsic role during viral infection, we reconstituted the *Rag2*^{-/-} mice with Thy1.2⁺ T cells isolated from WT or *Nlrp12*^{-/-#2} mice. Reconstituted mice were then infected with VSV, and weight loss and immune responses were monitored (Figure 7A). WT > *Rag2*^{-/-} mice had WT *Nlrp12*-expressing T cells, while *Nlrp12*^{-/-#2} > *Rag2*^{-/-} mice had *Nlrp12*^{-/-#2} T cells. These two chimeric *Rag2*^{-/-} strains

showed similar weight loss (Figure 7B), infiltrated CD4⁺ and CD8⁺ T cells, (Figure 7C) and IFN- γ levels in CD4⁺ or CD8⁺ cells in brain tissues by day 3 (Figure 7D) and day 9 (Figure S7) after VSV infection. These data indicate that *Nlrp12* in T cells did not affect VSV infection outcome.

To test the role of NLRP12 in myeloid cells, we generated tissue-specific, myeloid conditional *Nlrp12* knockout mice (*Nlrp12*^{flox/flox} LysM-Cre⁺) (Figure 7E) and littermate controls (*Nlrp12*^{flox/flox} LysM-Cre⁻) and infected these two groups with VSV. Mouse weight and survival were monitored for 22 days. The control mice had one weight drop at day 2 and another weight drop at day 6–7 post-infection, and the weight loss persisted for the duration of the study. By contrast, *Nlrp12*^{flox/flox} LysM-Cre⁺ mice did not display this second weight drop and recovered from day 7 onward (Figure 7F). In addition, one-third of the control mice died from the infection, while all of the *Nlrp12*^{flox/flox} LysM-Cre⁺ mice survived and recovered (Figure 7G). This indicates that myeloid-specific *Nlrp12* deficiency augments the host response and accelerates recovery during VSV infection.

We recently demonstrated that NLRP12 attenuates colon inflammation by maintaining colonic microbial diversity and promoting anti-inflammatory commensals such as *Lachnospiraceae* (Chen et al., 2017). To assess if the microbiota played a role in the resistant phenotypes observed in the *Nlrp12*-deficient mice, germ-free WT and *Nlrp12*^{-/-} littermate mice were infected with VSV. Germ-free WT mice were more sensitive to VSV infection than germ-free *Nlrp12*^{-/-} mice, exhibiting more weight loss (Figure 7H), more death (Figure 7I), and significantly lower levels of serum IFN- β and *ifnb* transcript (Figures 7J and 7K) but significantly higher VSV genomic RNA expression (Figure 7L) 24 h after VSV infection. In composite, these results indicate that myeloid NLRP12 attenuates host response against VSV infection but that this occurs regardless of the microbiota.

DISCUSSION

While several NLR proteins exhibit negative regulatory function, the precise molecular mechanism by which they mediate this inhibitory function *in vivo* or in primary cells is less clear. In this report, we show that *Nlrp12*-deficiency in human and mouse DCs leads to elevated amounts of cytokines such as IFN- β and TNF in response to VSV infection, the RIG-I agonists 5'pppdsRNA, and short poly(I:C). Mechanistically, NLRP12 interacts with TRIM25 to disrupt RIG-I and TRIM25 association and TRIM25-mediated Lys63-linked ubiquitination of RIG-I. The latter is required for RIG-I-mediated IFN- β production, achieved through its interaction with and activation of MAVS. *In vivo* infection shows that *Nlrp12*^{-/-} mice are more resistant to VSV infection, have lower viral loads, and recover faster than WT mice.

(H and I) Brains were harvested 12 h post-infection, and IFN- α (H) and TNF (I) in CD11b⁺CD11c⁺ DCs were measured by FACS. Histogram is from a representative sample (left), and data compilations from at least five mice (right) are expressed as mean $\pm$ SEM for each group. Student's t test shows *p < 0.05. Shaded histogram is the isotype control. Numbers represent mean fluorescence intensity (MFI).

(J) Body weight was monitored (n = 15 per group). WT mice (20%) died between days 5 and 6 (arrow). Student's t test shows *p < 0.05 or **p < 0.01. See Videos S1 and S2 for activity of VSV-infected WT and *Nlrp12*^{-/-#2} mice.

(K and L) Mouse brain section was stained with H&E (K) and anti-GFAP (L) by day 9 post-VSV infection. Five fields of H&E stained section were randomly selected and the numbers of neuron counted and represented as mean $\pm$ SD (see number under each panel). Black arrow: representative neuron with intact nuclear membrane and smooth and round contour. Blue arrows, inflammatory foci. (L) shows brown horseradish peroxidase immunostaining: reactive astrocyte.




Figure 7. *Nlrp12* Deficiency in Myeloid but Not T Cells Protects Host from VSV Infection in a Microbiota-Independent Manner

(A) Reconstitution of *Rag2*^{-/-} mice with T cells followed by VSV inoculation.

(B) Body weight was monitored (n = 4 per group).

(C and D) At day 3 post-infection, (C) Brain MNCs were assayed for CD4⁺ and CD8⁺ T cells and (D) expression of IFN-γ by brain CD4⁺ and CD8⁺ T cells as determined by FACS analysis.

(E) Scheme of *Nlrp12*^{fl/fl} production using a targeting construct, which contained loxP sites flanking exon 3 of *Nlrp12* next to a FRT flanked neomycin-resistance cassette in intron 2.

(F) Control *Nlrp12*^{fl/fl} LysM-Cre⁻ and *Nlrp12* KO (*Nlrp12*^{fl/fl} LysM-Cre⁺) mice were inoculated with VSV (1 × 10⁶ PFU) intranasally, and body weight loss was monitored (n = 9 per group). Multiple t test shows *p < 0.05.

(G) Survival rate is displayed as Kaplan–Meier survival curves with log rank test (n = 9 per group).

(legend continued on next page)

This is attributed to higher amounts of IFN- α and IFN- β in the peripheral blood and CNS of infected *Nlrp12*^{-/-} mice than in WT controls, and the effect is mediated by myeloid NLRP12. These *in vivo* outcomes provide evidence that NLRP12 is a negative regulator of the anti-viral innate immunity activated by RIG-I.

Several NLRs have been reported to reduce the production of IFN-I in response to diverse stimuli; however, in most cases, the precise pathway has not been identified or the studies were limited to *in vitro* analysis. For example, NLRC3 associates with STING and TBK1 to impede the STING-TBK1 interaction, thereby reducing the downstream DNA-virus-mediated type I IFN production (Zhang et al., 2014). NLRC5 interacts with RIG-I and MDA5 to inhibit RLR-mediated IFN-I responses (Cui et al., 2010), although reversed findings have been found by others (Benkő et al., 2017). NLRP4 regulates double-stranded RNA- or DNA-mediated production of IFN-I by recruiting the E3 ubiquitin ligase DTX4, thus targeting TBK1 for degradation *in vitro* (Cui et al., 2012). NLRX1 is a negative regulator of RIG-I-mediated IFN-I signaling pathway, binding to MAVS and blocking its interaction with RIG-I (Moore et al., 2008). Its interference with MAVS has also been observed in myocardial ischemia (Li et al., 2016), while NLRX1 itself can be a target of Fas-associated factor 1 (FAF1), which prevents its interaction with MAVS (Kim et al., 2017). However its negative effect on IFN-I is not always observed, and its role during a viral infection may vary depending on the time course, infectious dose, and/or viral proteins involved (Jaworska et al., 2014). Finally, NLRP14 expressed by germ cell has been reported to interact physically with STING, RIG-I, MAVS, and TBK1, leading to the ubiquitination and degradation of TBK1 (Abe et al., 2017). This suggests the intriguing possibility that NLRP14 inhibits nucleic acid sensing to prevent germ cells from inappropriate responses to exogenous nucleic acid.

This report shows that NLRP12 interacts with the E3 ubiquitin ligase TRIM25 to reduce TRIM25-mediated Lys63-linked ubiquitination of RIG-I, but it also enhances Lys48-linked ubiquitination of RIG-I mediated by RNF125, leading to its degradation. We demonstrate that an NLR protein modifies the post-translational modification of RIG-I by TRIM25, resulting in reduced IFN-I production in both cells and intact animals.

While the expression of most NLR mRNA and/or proteins is enhanced by microbial infection, human NLRP12 protein (Figures 4D and 4E) and transcript and murine *Nlrp12* transcript (Figures S2C and S2D) are downregulated by VSV infection. The reduction of *NLRP12/Nlrp12* expression may be one strategy by which the inhibitory effects of NLRP12 are relaxed when cells encounter a viral invasion, thus unleashing TRIM25 and RIG-I. The downregulation of NLR expression by microbial stimuli is also observed for another inhibitory NLR, NLRC3 (Schneider et al., 2012). Thus, downregulation of *Nlrp12* and *Nlrc3* expression provides a common mechanism by which the functions of these inhibitory NLRs are controlled. However, reduced

NLRP12 protein and mRNA expression cannot be the only mechanism that reduces NLRP12-RIG-I interaction, as VSV reduced NLRP12-TRIM25 association even when NLRP12 was under the control of an exogenous promoter (Figure 4D). Our study also shows that the impact of NLRP12 is most obvious at a lower MOI, while its influence wanes at higher MOIs. This may potentially have relevance during a cytokine storm elicited by a severe or vigorous viral infection, in which inflammatory cytokines are produced at high and potentially harmful levels and cannot be attenuated. Thus a cytokine storm may partly be attributed to the inability of inhibitors such as NLRP12 to mitigate this inflammatory response at a high MOI.

Others have reported that NLRP12 is an intrinsic regulator of T cells that negatively regulates T cell activation to augment autoreactivity (Gharagozloo et al., 2018). However, we did not observe an impact of NLRP12 in T-cell-mediated antiviral response. Instead, deletion of *Nlrp12* expression in myeloid cells augmented host resistance against VSV infection. These results indicate that *Nlrp12* in myeloid cells, but not T cells, is important for host response in the viral infection model tested here. In another paper, the presence of *Nlrp12* was found to enhance neutrophil migration upon influenza viral infection. Thus NLRP12 may exhibit different outcomes depending on the virus, route of infection, the dosage of virus used to cause pathology, and the genetic background (Hornick et al., 2018). For example, in our study, we noted that the attenuating effect of NLRP12 diminishes with greater viral load (Figure 1L). In both the colitis model reported previously (Allen et al., 2012; Zaki et al., 2011) and the viral infection model studied here, NLRP12 serves to attenuate inflammatory response. The colitis model showed increased inflammatory cytokines such as TNF and IL-6, whereas the current work focuses on increased type I interferons (IFN-I) in *Nlrp12*^{-/-} mice. However, we also find that TNF is elevated (Figures 1B and 6I) in *Nlrp12*^{-/-} mice infected with the virus. Thus findings in the colitis model and the viral infection study reported here are consistent. However a major difference between the two models is the involvement of the microbiome. It has been reported that NLRP12 attenuates colitis by promoting protective commensal bacterial growth (Chen et al., 2017). Our experiment did not show a role for the microbiota during VSV infection. In the colitis study, we observed elevated basal immune signaling in *Nlrp12*^{-/-} mice that is independent of the gut microbiota. Elevated immune signals observed at the basal stage in *Nlrp12*^{-/-} mice likely contribute to the greater immune activation observed in viral infection. Finally, accumulating evidence demonstrates that sustained and abnormal activation of RLRs can cause autoimmune diseases resulting from elevated interferons (Kato et al., 2017). In addition to inflammatory disorders such as colitis, NLRP12 may also offer clues for patients suffering from interferonopathy-based autoimmunity.

In summary, a balance between positive and negative regulatory loops is crucial for maintaining homeostasis. This work

(H) Germ-free WT and *Nlrp12*^{-/-} mice were inoculated with VSV intranasally. Body weight was monitored (n = 5 per group).

(I) Same as (G), except germ-free mice were used (n = 5 per group), *p < 0.05.

(J) Serum IFN- β was measured by ELISA at 24 h post-infection.

(K) *Ifnb* transcript in brain tissue was measured by real time qPCR analysis.

(L) Brain-localized viral titers were determined by plaque assays.

For (H), (J), (K), and (L), Mann-Whitney test was performed, *p < 0.05.

supports the model that, under resting conditions, NLRP12 in the myeloid lineage interacts with TRIM25 to prevent RIG-I activation by inhibiting TRIM25-RIG-I interaction and Lys63-linked ubiquitination of RIG-I. During a viral infection, NLRP12-mediated inhibition is relieved by its reduced expression and possibly other mechanisms which unleash RIG-I-mediated signaling. In the absence of NLRP12, phosphorylated NF- κ B p65 and IRF3 are increased and host anti-viral response is freed and/or accelerated. Other works have shown that NLRP12 is essential for the maintenance of tumor suppression, gut commensals, and the prevention of autoimmunity. Thus, the presence of NLRP12 is important for maintaining homeostasis and serves as a check-point of innate immune response.

STAR★METHODS

Detailed methods are provided in the online version of this paper and include the following:

- **KEY RESOURCES TABLE**
- **CONTACT FOR REAGENT AND RESOURCE SHARING**
- **EXPERIMENTAL MODEL AND SUBJECT DETAILS**
 - Animals and Housing
 - Human Subjects
 - Virus
- **METHOD DETAILS**
 - Cell Preparation
 - Virus Infection and Ligand Stimulation of Human moDC and Mouse BMDM
 - RNA Isolation and mRNA Analysis
 - Transfection and Luciferase Reporter Analysis
 - Human *NLRP12* Knockdown Experiment
 - Co-immunoprecipitation and Ubiquitination Assays
 - Viral Genome Quantification and Determination of Virus Titer
 - Confocal Microscopy, Histopathology and Immunohistochemistry
 - Experimental VSV Infection Mouse Model and T Cell Adoptive Transfer
 - Isolation of Mononuclear Cells from the CNS and Flow Cytometry Analysis
- **QUANTIFICATION AND STATISTICAL ANALYSIS**

SUPPLEMENTAL INFORMATION

Supplemental Information includes can be found with this article online at <https://doi.org/10.1016/j.chom.2019.02.013>.

ACKNOWLEDGMENTS

This work was supported by the National Institutes of Health, United States U19-AI109965, DK094779, CA156330 and AI029564 (J.P.-Y.T.); National Science Council, Taiwan NSC 103-2320-B-038-004-MY2; Ministry of Science and Technology, Taiwan MOST 104-2320-B-010-0440-MY3; National Yang-Ming University School of Medicine of Development and Construction program 107F-MOI; and the Cancer Progression Research Center, National Yang-Ming University, from the Higher Education Sprout Project by the Ministry of Education (MOE) in Taiwan. We thank the following for core and technical support: National Yang-Ming University Imaging Core Facility, Flow Cytometry Core Facility, Animal Studies Core Facility and Taiwan Animal Consortium, Taiwan Mouse Clinic, UNC Animal Models Core, Animal Histopathology

Core Facility, and Animal Studies Core Facility. We thank Dr. S.-L.H. for providing critical reagents.

AUTHOR CONTRIBUTIONS

S.-T.C. and J.P.-Y.T. designed the experiments. L.C., D.S.-C.L., S.-Y.C., Y.-P.T., W.-T.T., F.-J.L., H.G., J.W.T., C.-W.C., W.J.B., M.-J.S., and H.-R.K. assisted with the experiments. J.U.J. and D.I. provided critical reagents. J.P.-Y.T. and S.-T.C. supervised the study. S.-T.C. and J.P.-Y.T. interpreted the data and wrote the manuscript. All authors reviewed the manuscript.

DECLARATION OF INTERESTS

The authors declare no competing interests.

Received: November 8, 2017

Revised: August 12, 2018

Accepted: January 15, 2019

Published: March 19, 2019

REFERENCES

- Abe, T., Lee, A., Sitharam, R., Kesner, J., Rabadan, R., and Shapira, S.D. (2017). Germ-cell-specific inflammasome component NLRP14 negatively regulates cytosolic nucleic acid sensing to promote fertilization. *Immunity* 46, 621–634.
- Allen, I.C., Wilson, J.E., Schneider, M., Lich, J.D., Roberts, R.A., Arthur, J.C., Woodford, R.M., Davis, B.K., Uronis, J.M., Herfarth, H.H., et al. (2012). NLRP12 suppresses colon inflammation and tumorigenesis through the negative regulation of noncanonical NF- κ B signaling. *Immunity* 36, 742–754.
- Arimoto, K., Takahashi, H., Hishiki, T., Konishi, H., Fujita, T., and Shimotohno, K. (2007). Negative regulation of the RIG-I signaling by the ubiquitin ligase RNF125. *Proc. Natl. Acad. Sci. USA* 104, 7500–7505.
- Arthur, J.C., Lich, J.D., Ye, Z., Allen, I.C., Gris, D., Wilson, J.E., Schneider, M., Roney, K.E., O'Connor, B.P., Moore, C.B., et al. (2010). Cutting edge: NLRP12 controls dendritic and myeloid cell migration to affect contact hypersensitivity. *J. Immunol.* 185, 4515–4519.
- Ataide, M.A., Andrade, W.A., Zamboni, D.S., Wang, D., Souza, Mdo.C., Franklin, B.S., Elian, S., Martins, F.S., Pereira, D., Reed, G., et al. (2014). Malaria-induced NLRP12/NLRP3-dependent caspase-1 activation mediates inflammation and hypersensitivity to bacterial superinfection. *PLoS Pathog.* 10, e1003885.
- Benkő, S., Kovács, E.G., Hezel, F., and Kufer, T.A. (2017). NLR5 functions beyond MHC I regulation-what do we know so far? *Front. Immunol.* 8, 150.
- Broz, P., and Dixit, V.M. (2016). Inflammasomes: mechanism of assembly, regulation and signalling. *Nat. Rev. Immunol.* 16, 407–420.
- Cai, S., Batra, S., Del Piero, F., and Jeyaseelan, S. (2016). NLRP12 modulates host defense through IL-17A-CXCL1 axis. *Mucosal Immunol.* 9, 503–514.
- Chen, S.T., Lin, Y.L., Huang, M.T., Wu, M.F., Cheng, S.C., Lei, H.Y., Lee, C.K., Chiou, T.W., Wong, C.H., and Hsieh, S.L. (2008). CLEC5A is critical for dengue-virus-induced lethal disease. *Nature* 453, 672–676.
- Chen, S.T., Liu, R.S., Wu, M.F., Lin, Y.L., Chen, S.Y., Tan, D.T., Chou, T.Y., Tsai, I.S., Li, L., and Hsieh, S.L. (2012). CLEC5A regulates Japanese encephalitis virus-induced neuroinflammation and lethality. *PLoS Pathog.* 8, e1002655.
- Chen, L., Wilson, J.E., Koenigsnecht, M.J., Chou, W.C., Montgomery, S.A., Truax, A.D., Brickey, W.J., Packey, C.D., Maharshak, N., Matsushima, G.K., et al. (2017). NLRP12 attenuates colon inflammation by maintaining colonic microbial diversity and promoting protective commensal bacterial growth. *Nat. Immunol.* 18, 541–551.
- Cui, J., Zhu, L., Xia, X., Wang, H.Y., Legras, X., Hong, J., Ji, J., Shen, P., Zheng, S., Chen, Z.J., and Wang, R.F. (2010). NLR5 negatively regulates the NF- κ B and type I interferon signaling pathways. *Cell* 141, 483–496.
- Cui, J., Li, Y., Zhu, L., Liu, D., Songyang, Z., Wang, H.Y., and Wang, R.F. (2012). NLRP4 negatively regulates type I interferon signaling by targeting

- the kinase TBK1 for degradation via the ubiquitin ligase DTX4. *Nat. Immunol.* **13**, 387–395.
- Davis, B.K., Wen, H., and Ting, J.P. (2011). The inflammasome NLRs in immunity, inflammation, and associated diseases. *Annu. Rev. Immunol.* **29**, 707–735.
- Detje, C.N., Lienenklaus, S., Chhatbar, C., Spanier, J., Prajeeth, C.K., Soldner, C., Tovey, M.G., Schlüter, D., Weiss, S., Stangel, M., and Kalinke, U. (2015). Upon intranasal vesicular stomatitis virus infection, astrocytes in the olfactory bulb are important interferon Beta producers that protect from lethal encephalitis. *J. Virol.* **89**, 2731–2738.
- Gack, M.U., Shin, Y.C., Joo, C.H., Urano, T., Liang, C., Sun, L., Takeuchi, O., Akira, S., Chen, Z., Inoue, S., and Jung, J.U. (2007). TRIM25 RING-finger E3 ubiquitin ligase is essential for RIG-I-mediated antiviral activity. *Nature* **446**, 916–920.
- Gharagozloo, M., Mahvelati, T.M., Imbeault, E., Gris, P., Zerif, E., Bobbala, D., Ilangumaran, S., Amrani, A., and Gris, D. (2015). The nod-like receptor, Nlrp12, plays an anti-inflammatory role in experimental autoimmune encephalomyelitis. *J. Neuroinflammation* **12**, 198.
- Gharagozloo, M., Mahmoud, S., Simard, C., Mahvelati, T.M., Amrani, A., and Gris, D. (2018). The dual immunoregulatory function of *Nlrp12* in T cell-mediated immune response: lessons from experimental autoimmune encephalomyelitis. *Cells* **7**, E119.
- Hartwell, L.H., and Weinert, T.A. (1989). Checkpoints: controls that ensure the order of cell cycle events. *Science* **246**, 629–634.
- Hornick, E.E., Banoth, B., Miller, A.M., Zacharias, Z.R., Jain, N., Wilson, M.E., Gibson-Corley, K.N., Legge, K.L., Bishop, G.A., Sutterwala, F.S., and Cassel, S.L. (2018). Nlrp12 mediates adverse neutrophil recruitment during influenza virus infection. *J. Immunol.* **200**, 1188–1197.
- Hornung, V., Ellegast, J., Kim, S., Brzózka, K., Jung, A., Kato, H., Poeck, H., Akira, S., Conzelmann, K.K., Schlee, M., et al. (2006). 5'-Triphosphate RNA is the ligand for RIG-I. *Science* **314**, 994–997.
- Jaworska, J., Coulombe, F., Downey, J., Tzelepis, F., Shalaby, K., Tattoli, I., Berube, J., Rousseau, S., Martin, J.G., Girardin, S.E., et al. (2014). NLRX1 prevents mitochondrial induced apoptosis and enhances macrophage antiviral immunity by interacting with influenza virus PB1-F2 protein. *Proc. Natl. Acad. Sci. USA* **111**, E2110–E2119.
- Kato, H., Oh, S.W., and Fujita, T. (2017). RIG-I-Like Receptors and Type I Interferonopathies. *J. Interferon Cytokine Res.* **37**, 207–213.
- Kawai, T., Takahashi, K., Sato, S., Coban, C., Kumar, H., Kato, H., Ishii, K.J., Takeuchi, O., and Akira, S. (2005). IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction. *Nat. Immunol.* **6**, 981–988.
- Kim, J.H., Park, M.E., Nikapitiya, C., Kim, T.H., Uddin, M.B., Lee, H.C., Kim, E., Ma, J.Y., Jung, J.U., Kim, C.J., and Lee, J.S. (2017). FAS-associated factor-1 positively regulates type I interferon response to RNA virus infection by targeting NLRX1. *PLoS Pathog.* **13**, e1006398.
- Krauss, J.L., Zeng, R., Hickman-Brecks, C.L., Wilson, J.E., Ting, J.P., and Novack, D.V. (2015). NLRP12 provides a critical checkpoint for osteoclast differentiation. *Proc. Natl. Acad. Sci. USA* **112**, 10455–10460.
- Kufer, T.A., and Sansonetti, P.J. (2011). NLR functions beyond pathogen recognition. *Nat. Immunol.* **12**, 121–128.
- Li, H., Zhang, S., Li, F., and Qin, L. (2016). NLRX1 attenuates apoptosis and inflammatory responses in myocardial ischemia by inhibiting MAVS-dependent NLRP3 inflammasome activation. *Mol. Immunol.* **76**, 90–97.
- Lich, J.D., Williams, K.L., Moore, C.B., Arthur, J.C., Davis, B.K., Taxman, D.J., and Ting, J.P. (2007). Monarch-1 suppresses non-canonical NF-kappaB activation and p52-dependent chemokine expression in monocytes. *J. Immunol.* **178**, 1256–1260.
- Lu, C., Xu, H., Ranjith-Kumar, C.T., Brooks, M.T., Hou, T.Y., Hu, F., Herr, A.B., Strong, R.K., Kao, C.C., and Li, P. (2010). The structural basis of 5' triphosphate double-stranded RNA recognition by RIG-I C-terminal domain. *Structure* **18**, 1032–1043.
- Lukens, J.R., Gurung, P., Shaw, P.J., Barr, M.J., Zaki, M.H., Brown, S.A., Vogel, P., Chi, H., and Kanneganti, T.D. (2015). The NLRP12 sensor negatively regulates autoinflammatory disease by modulating interleukin-4 production in T cells. *Immunity* **42**, 654–664.
- Mao, A.P., Li, S., Zhong, B., Li, Y., Yan, J., Li, Q., Teng, C., and Shu, H.B. (2010). Virus-triggered ubiquitination of TRAF3/6 by cIAP1/2 is essential for induction of interferon-beta (IFN-beta) and cellular antiviral response. *J. Biol. Chem.* **285**, 9470–9476.
- Moore, C.B., Bergstralh, D.T., Duncan, J.A., Lei, Y., Morrison, T.E., Zimmermann, A.G., Accavitti-Loper, M.A., Madden, V.J., Sun, L., Ye, Z., et al. (2008). NLRX1 is a regulator of mitochondrial antiviral immunity. *Nature* **451**, 573–577.
- Papale, A., Kummer, E., Galbiati, V., Marinovich, M., Galli, C.L., and Corsini, E. (2017). Understanding chemical allergen potency: role of NLRP12 and Blimp-1 in the induction of IL-18 in human keratinocytes. *Arch. Toxicol.* **91**, 1783–1794. Published online September 1, 2016.
- Peisley, A., Wu, B., Xu, H., Chen, Z.J., and Hur, S. (2014). Structural basis for ubiquitin-mediated antiviral signal activation by RIG-I. *Nature* **509**, 110–114.
- Pichlmair, A., Schulz, O., Tan, C.P., Näsund, T.I., Liljeström, P., Weber, F., and Reis e Sousa, C. (2006). RIG-I-mediated antiviral responses to single-stranded RNA bearing 5'-phosphates. *Science* **314**, 997–1001.
- Saha, S.K., Pietras, E.M., He, J.Q., Kang, J.R., Liu, S.Y., Oganessian, G., Shahangian, A., Zarnegar, B., Shiba, T.L., Wang, Y., and Cheng, G. (2006). Regulation of antiviral responses by a direct and specific interaction between TRAF3 and Cardif. *EMBO J.* **25**, 3257–3263.
- Schneider, M., Zimmermann, A.G., Roberts, R.A., Zhang, L., Swanson, K.V., Wen, H., Davis, B.K., Allen, I.C., Holl, E.K., Ye, Z., et al. (2012). The innate immune sensor NLRC3 attenuates Toll-like receptor signaling via modification of the signaling adaptor TRAF6 and transcription factor NF- κ B. *Nat. Immunol.* **13**, 823–831.
- Seth, R.B., Sun, L., Ea, C.K., and Chen, Z.J. (2005). Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-kappaB and IRF 3. *Cell* **122**, 669–682.
- Silveira, T.N., Gomes, M.T., Oliveira, L.S., Campos, P.C., Machado, G.G., and Oliveira, S.C. (2017). NLRP12 negatively regulates proinflammatory cytokine production and host defense against *Brucella abortus*. *Eur. J. Immunol.* **47**, 51–59.
- Sofroniew, M.V., and Vinters, H.V. (2010). Astrocytes: biology and pathology. *Acta Neuropathol.* **119**, 7–35.
- Tan, X., Sun, L., Chen, J., and Chen, Z.J. (2018). Detection of microbial infections through innate immune sensing of nucleic acids. *Annu. Rev. Microbiol.* **72**, 447–478.
- Ting, J.P., Duncan, J.A., and Lei, Y. (2010). How the noninflammasome NLRs function in the innate immune system. *Science* **327**, 286–290.
- Truax, A.D., Chen, L., Tam, J.W., Cheng, N., Guo, H., Koblansky, A.A., Chou, W.C., Wilson, J.E., Brickey, W.J., Petrucelli, A., et al. (2018). The inhibitory innate immune sensor NLRP12 maintains a threshold against obesity by regulating gut microbiota homeostasis. *Cell Host Microbe* **24**, 364–378.e6.
- Ulland, T.K., Jain, N., Hornick, E.E., Elliott, E.I., Clay, G.M., Sadler, J.J., Mills, K.A., Janowski, A.M., Volk, A.P., Wang, K., et al. (2016). Nlrp12 mutation causes C57BL/6J strain-specific defect in neutrophil recruitment. *Nat. Commun.* **7**, 13180.
- Vladimer, G.I., Weng, D., Paquette, S.W., Vanaja, S.K., Rathinam, V.A., Aune, M.H., Conlon, J.E., Burbage, J.J., Proulx, M.K., Liu, Q., et al. (2012). The NLRP12 inflammasome recognizes *Yersinia pestis*. *Immunity* **37**, 96–107.
- Wang, L., Manji, G.A., Grenier, J.M., Al-Garawi, A., Merriam, S., Lora, J.M., Geddes, B.J., Briskin, M., DiStefano, P.S., and Bertin, J. (2002). PYPAF7, a novel PYRIN-containing Apaf1-like protein that regulates activation of NF-kappa B and caspase-1-dependent cytokine processing. *J. Biol. Chem.* **277**, 29874–29880.
- Wang, P., Zhu, S., Yang, L., Cui, S., Pan, W., Jackson, R., Zheng, Y., Rongvaux, A., Sun, Q., Yang, G., et al. (2015). Nlrp6 regulates intestinal antiviral innate immunity. *Science* **350**, 826–830.

- Yoneyama, M., Kikuchi, M., Natsukawa, T., Shinobu, N., Imaizumi, T., Miyagishi, M., Taira, K., Akira, S., and Fujita, T. (2004). The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. *Nat. Immunol.* **5**, 730–737.
- Zaki, M.H., Vogel, P., Malireddi, R.K., Body-Malapel, M., Anand, P.K., Bertin, J., Green, D.R., Lamkanfi, M., and Kanneganti, T.D. (2011). The NOD-like receptor NLRP12 attenuates colon inflammation and tumorigenesis. *Cancer Cell* **20**, 649–660.
- Zaki, M.H., Man, S.M., Vogel, P., Lamkanfi, M., and Kanneganti, T.D. (2014). Salmonella exploits NLRP12-dependent innate immune signaling to suppress host defenses during infection. *Proc. Natl. Acad. Sci. USA* **111**, 385–390.
- Zamoshnikova, A., Groß, C.J., Schuster, S., Chen, K.W., Wilson, A., Tacchini-Cottier, F., and Schroder, K. (2016). NLRP12 is a neutrophil-specific, negative regulator of in vitro cell migration but does not modulate LPS- or infection-induced NF- κ B or ERK signalling. *Immunobiology* **221**, 341–346.
- Zhang, L., Mo, J., Swanson, K.V., Wen, H., Petrucelli, A., Gregory, S.M., Zhang, Z., Schneider, M., Jiang, Y., Fitzgerald, K.A., et al. (2014). NLRC3, a member of the NLR family of proteins, is a negative regulator of innate immune signaling induced by the DNA sensor STING. *Immunity* **40**, 329–341.

STAR★METHODS

KEY RESOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Antibodies		
Rabbit anti-mouse pp65 (Ser536) (clone 93H1)	Cell Signaling	Cat# 3033 RRID:AB_331284
Rabbit anti-mouse p65 (clone, D14E12)	Cell Signaling	Cat# 8242 RRID:AB_10859369
Rabbit anti-mouse p-IRF3 (Ser396) (clone 4D4G)	Cell Signaling	Cat# 4947 RRID:AB_823547
Rabbit anti-mouse IRF3 (clone D83B9)	Cell Signaling	Cat# 4302 RRID:AB_1904036
Rabbit anti-MAVS (Rodent Specific)	Cell Signaling	Cat# 4983 RRID:AB_823566
Rabbit anti-NFκB2 p100/p52	Cell Signaling	Cat# 4882 RRID:AB_2153403
Rabbit anti- pTBK1 (Ser172) (clone D52C2)	Cell Signaling	Cat# 5483 RRID:AB_823547
Rabbit anti-TBK1 (clone D1B4)	Cell Signaling	Cat# 3504 RRID:AB_2255663
Rabbit anti-RIG-I (clone D14G6)	Cell Signaling	Cat# 3743 RRID:AB_2269233
Rabbit anti-K63-linkage polyubiquitin (clone D7A11)	Cell Signaling	Cat# 5621 RRID:AB_10827985
Rabbit anti-K48-linkage polyubiquitin	Cell Signaling	Cat# 4289 RRID:AB_10557239
HA-Tag mouse antibody HRP conjugate (clone 6E2)	Cell Signaling	Cat# 2999 RRID:AB_1264166
GAPDH Rabbit antibody HRP conjugate (clone 14C10)	Cell Signaling	Cat# 2999 RRID:AB_1264166
Mouse Anti-GFAP Monoclonal Antibody (clone GA5)	Cell Signaling	Cat# 3670 RRID:AB_561049
Rabbit anti-EFP (TRIM25) (clone H-300)	Santa Cruz	Cat# sc-22832 RRID:AB_2241104
Rabbit anti-TRAC1 (RNF125) (clone, C-17)	Santa Cruz	Cat# sc-85188 RRID:AB_2182278
Mouse anti-mouse p52 (clone, C-5)	Santa Cruz	Cat# sc-7386 RRID:AB_2267131
Rabbit anti-MAVS (clone, H-135)	Santa Cruz	Cat# sc-1565327 RRID:AB_2267131
Rabbit anti-TRAF6 (clone, H-274)	Santa Cruz	Cat# sc-7221 RRID:AB_793346
Rabbit anti-TRAF3 (clone, G-6)	Santa Cruz	Cat# sc-6933 RRID:AB_628390
Rabbit anti-IRF3 (clone, FL-425)	Santa Cruz	Cat# sc-9082 RRID:AB_2264929
Rabbit anti-IKKα (clone, H-744)	Santa Cruz	Cat# sc-7218 RRID:AB_2079399
Rabbit anti-NLRP12	Thermo Fisher	Cat# PA5-21027 RRID:AB_11152858
Rabbit anti-NLRP12 (N-term)	Abgent	Cat# AP14014a RRID:AB_10893749

(Continued on next page)

Continued

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Goat anti-rabbit IgG HRP	Jackson ImmunoResearch Laboratories	Cat# 111-035-144 RRID:AB_2307391
Goat anti-mouse IgG HRP	Jackson ImmunoResearch Laboratories	Cat# 115-035-146 RRID:AB_2307392
Anti- mouse F4/80-Alexa Fluor 647 (clone A3-1)	Bio-Rad (formerly AbD Serotec)	Cat#MCA497RT RRID:AB_1102558
Anti- mouse IFN- γ -Alexa Fluor 700 (clone XMG-1.2)	BioLegend	Cat# 505823 RRID:AB_2561299
Anti- mouse RIG-I Alexa Fluor 488 (clone D-12)	Santa Cruze	Cat# sc- 376845 RRID:AB_2732794
Anti-mouse CD11b-Alexa Fluor 647 (clone M1/70)	BioLegend	Cat# 101220 RRID:AB_493546
Anti-mouse Ly6G-FITC (clone 1A8)	BioLegend	Cat# 127605 RRID:AB_1236488
Anti-mouse Ly6C-PE (clone HK 1.4)	BioLegend	Cat# 128007 RRID:AB_1186133
Anti-mouse CD11c-BV421 (clone HL3)	BD	Cat# 562782 unavailable
Anti-mouse CD3e- PE (clone 145-2C11)	BD	Cat# 553064 RRID:AB_394597
Anti-mouse CD3e- APC/Cy7 (clone 145-2C11)	BD	Cat# 557596 RRID:AB_396759
Anti- mouse CD4-APC (clone L3T4)	BD	Cat# 553051 RRID:AB_398528
Anti-mouse CD8a-Alexa Fluor 488 (clone 53-6.7)	BioLegend	Cat#100726 RRID:AB_2565953
Anti-mouse IFN- α -FITC (clone RMMA-1)	pbl	Cat#22100-3 RRID:AB_2565953
Anti-mouse TNF-APC/Cy7 (clone MP6-XT22)	Biolegend	Cat# 506344 RRID:AB_2565953
MouseThy1.2 (CD90.2) magnetic beads	Miltenyi Biotec	Cat# 130-049-101
Human CD14 magnetic beads	Miltenyi Biotec	Cat# 130-050-201
Bacterial and Virus Strains		
Vesicular stomatitis virus, Indiana strain	ATCC	ATCC VR-1419
Chemicals, Peptides, and Recombinant Proteins		
Recombinant murine GM-CSF	PEPROTECH	Cat# 315-03
CytoFix/perm solution	BD Bioscience	Cat# 554714
Recombinant human GM-CSF	PEPROTECH	Cat# 300-03
Recombinant human IL-4	PEPROTECH	Cat# 200-04
HA-agarose beads	Sigma	Cat# A2095
Flag-M2 affinity gel	Sigma	Cat# A2220
Alexa Fluor 488 Phalloidin	Thermo Scientific	Cat# A12379
mito-tracker® Deep Red FM	Cell Signaling	Cat# 8778
Percoll	GE Healthcare	Cat# GE17-0891-01
Bovine serum albumin	Sigma	Cat# A4919
Poly (I:C)-LMW/LyoVec	Sigma	Cat# tirl-picwlv
5'ppp-dsDNA	Invivogen	Cat# tirl-3prna
Collagenase IV	Sigma	Cat# C5138
DNase I	Sigma	Cat# D5025
Critical Commercial Assays		
Lipofectamine™ 2000	Thermo Scientific	Cat# 11668019
HiPerFect Transfection reagent	QIAGEN	Cat# 301704

(Continued on next page)

Continued

REAGENT or RESOURCE	SOURCE	IDENTIFIER
QIAamp RNA Mini Kit	QIAGEN	Cat# 52904
Dual-Glo Luciferase Assay System	Promega	Cat# E2920
Mouse IFN- β ELISA assay kit	R&D System	Cat# DY8234-05
Mouse TNF ELISA assay kit	R&D System	Cat# DY410-05
TRIzolTM Reagent	Thermo Scientific	Cat# 15596026
ReverAid first strand cDNA Synthesis kit	Thermo Scientific	Cat# K1622
chromogen diaminobenzidine (DAB)	DAKO	Cat# K3468
SYBR TM Green PCR Master Mix	Thermo Scientific	Cat# BIO-98005
Experimental Models: Cell Lines		
Bone marrow derived macrophages (BMDM)	In this paper	NA
Bone marrow derived dendritic cells (BMDC)	In this paper	NA
Human monocyte derived dendritic (MoDC)	In this paper	NA
HEK293 cells	ATCC	Cat# CLR-1573
Experimental Models: Organisms/Strains		
Mouse: wildtype C57B6/J	The Jackson lab	Cat#000664
Mouse: <i>Nlrp12</i> ^{-/-} mice	Allen et al., 2012	NA
Mouse: <i>Nlrp12</i> ^{-/-#2}	In this paper	NA
Mouse: <i>Nlrp12</i> ^{flox/flox} LysM-Cre ⁺	In this paper	NA
Oligonucleotides		
Mouse <i>Irfn</i> - β forward: 5'-CCACCACTCATTCTGAGGCA-3'	In this paper	NA
Mouse <i>Irfn</i> - β reversed: 5'-ATGGTGGTCCGAGCAGAGAT-3'	In this paper	NA
Mouse <i>Irfn</i> - α 4 forward: 5'-TACTCAGCAGACCTTGAACT-3'	In this paper	NA
Mouse <i>Irfn</i> - α 4 reversed: 5'-CAGTCTTGGCAGCAAGTTGAC-3'	In this paper	NA
Mouse <i>Nlrp12</i> forward: 5'-CCTCTTTGAGCCAGACGAAG-3'	In this paper	NA
Mouse <i>Nlrp12</i> reversed: 5'-GCCAGTCCAACATCACTTT-3'	In this paper	NA
Human <i>NLRP12</i> forward: 5'-CAGACTCCAGAACTGTGG-3'	In this paper	NA
Human <i>NLRP12</i> reversed: 5'-GCGTTGTTGGTCAGGTAAAG-3'	In this paper	NA
VSV genome forward: 5'-ACGGCGTACTTCCAGATGG-3'	In this paper	NA
VSV genome reserved: 5'-TCGGTTCAAGATCCAGG-3'	In this paper	NA
Recombinant DNA		
IFN- β luciferase reporter	Zhang et al., 2014	
ISRE luciferase reporter	Zhang et al., 2014	
NF- κ B luciferase reporter	Zhang et al., 2014	
pLR-TK	Zhang et al., 2014	
pFlag-CMV2-RIG-I	Zhang et al., 2014	
pCMV2/Flag-TBK1	Zhang et al., 2014	
pCMV2/Flag-IRF3	Zhang et al., 2014	
pCMV2/Flag-MAVS	Lich et al., 2007	
pCMV2/Flag-STING	Lich et al., 2007	
pCDNA3/HA-NLRP12	Lich et al., 2007	

(Continued on next page)

Continued

REAGENT or RESOURCE	SOURCE	IDENTIFIER
pCDNA3/V5-NLRP12	Lich et al., 2007	
All of the pCDNA3/V5-NLRP12 truncated mutants	Lich et al., 2007	
pCDNA3/HA-NLRX1	Zhang et al., 2014	
pCDNA3/V5-TRIM25	Gack et al., 2007	
pCDNA3/Myc-TRAF3	Schneider et al., 2012	
pCMV6/Myc-DDK-RNF125	OriGene	Cat# 204578
Software and Algorithms		
ImageJ X64	NA	https://imagej.nih.gov/ij/
Flowjo	FLOWJO, LLC	https://www.flowjo.com/
Prism	GraphPad	http://www.graphpad.com/scientific-software/prism/

CONTACT FOR REAGENT AND RESOURCE SHARING

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Jenny P-Y Ting (jenny_ting@med.unc.edu).

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Animals and Housing

All studies with *Nlrp12*^{-/-} were conducted in accordance with the UNC Chapel Hill IACUC approved animal protocol (#12-106) and Guide for the Care and Use of Laboratory Animals, while studies involving *Nlrp12*^{-/-#2} were in compliance with the Guide for the Care and Use of Laboratory Animals of the Taiwanese Council of Agriculture in a protocol approved by the Institutional Animal Care and Use Committee (IACUC) of National Yang-Ming University (IACUC #1060201). All mice were housed under specific-pathogen-free (SPF) conditions. *Nlrp12*^{-/-} mice were originally provided by Millenium Pharmaceutical and previously studied by us; these were backcrossed for at least nine generation onto the C57BL/6J background ([Allen et al., 2012](#)). WT and *Nlrp12*^{-/-} mice in this study were generated from common *Nlrp12*^{+/-} parents, and experiments used littermate controls, or their immediate descendants. Germ-free mice were derived by sterile embryo transfer by the National Gnotobiotic Rodent Resource Center at UNC- Chapel Hill ([Chen et al., 2017](#)). A second *Nlrp12*-deficient (*Nlrp12*^{-/-#2}) strain was generated at the Transgenic Mouse Model Core under the National Core Facility Program for Biotechnology in Taiwan using the CRISPR/Cas9 system and housed at the SPF animal core of National Yang-Ming University. The generation of this second gene-deficient strain was necessitated by our inability to obtain a Material Transfer agreement from the original source to ship these mice to Taiwan. A single guide RNA (sgRNA) containing a targeting sequence (crRNA sequence) at exon 1 of the *Nlrp12* allele and tracer RNA sequence were designed and generated, and the donor vector containing homologous sequence and a new insertion of three stop codons at exon 1 were injected into C57BL/6J blastocysts with Cas9 mRNA and sgRNA. Genotyping was performed by PCR analysis with *Nlrp12* 3 × stop primer, followed by digesting with Ase I restriction enzyme to determine the homozygosity and heterozygosity of stop codons knock-in *Nlrp12* allele ([Figure S1](#)). The sequence of sgRNA was input into the website <http://benchling.com/sign> to check for potential off-target sites. The off-target test was carried out in two founders, and no off-target effect was seen at all potential risk sites. For the myeloid-specific *Nlrp12*-deficient mice, *Nlrp12*^{flox/flox} mice were generated at the UNC Animal Models Core using a targeting construct, which contained the loxP sites flanking exon 3 of *Nlrp12*, next to a FRT flanked neomycin resistance cassette inserted in the intron 2. Targeted ES cells were injected into C57BL/6J-albino blastocysts, and the resulting male chimera offsprings were mated with female Rosa26-Flpe mice on a C57BL/6J-albino background to create heterozygous *Nlrp12*^{flox/+} mice and to remove the neomycin cassette. The *Nlrp12*^{flox/+} offsprings were then bred with C57BL/6J mice for at least another seven generations before they were inbred to obtain the *Nlrp12*^{flox/flox} control mice. *Nlrp12*^{flox/flox} mice were then crossed with LysM-Cre mice to generate the F1 generation. *Nlrp12*^{flox/flox} LysM-Cre⁺ and *Nlrp12*^{flox/flox} LysM-Cre⁻ (control) littermates from the F2 generation were used for future breeders or experiments. Myeloid-specific *Nlrp12* KO (*Nlrp12*^{flox/flox} LysM-Cre⁺) mice and control littermates (*Nlrp12*^{flox/flox} LysM-Cre⁻) were genotyped and cohoused before the VSV infection experiment. *Rag2*^{-/-} mice were originally from the Jackson Laboratory and were housed under SPF conditions before animal experiment at National Yang Ming University.

Human Subjects

Human whole blood was obtained from healthy donors at the Taipei Blood Center of the Taiwan Blood Services Foundation, under a protocol (AS-IRB02-103202) approved by the IRB of the Clinical Center of the Department of Health, Taiwan. Written informed consent was obtained from all donors.

Virus

Vesicular stomatitis virus-Indiana strain (VSV), originally obtained from ATCC (ATCC VR-1419), was grown in the Vero cell. Vero cells were infected with VSV (multiplicity of infection, MOI of 0.01), and virus was harvested from culture supernatants 48 h post-infection. Virus titers were determined by plaque formation in Vero cells with an overlay medium containing 1% methyl cellulose in complete DMEM medium (Life Technologies). VSV-infected cells were fixed with 0.2% of crystal violet in a 20% ethanol buffer to visualize plaques by 4 days post-infection. VSV-Indiana strain was used for *in vitro* and *in vivo* experiments throughout this study.

METHOD DETAILS

Cell Preparation

Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood of healthy human donors by standard density-gradient centrifugation with Ficoll-Paque (Amersham Biosciences). CD14⁺ cells were purified from PBMCs by high-gradient magnetic sorting, using the VarioMACS technique with anti-CD14 microbeads (Miltenyi Biotec GmbH). Cells were then cultured in complete RPMI 1640 medium (Life Technologies) supplemented with 10% (v/v) fetal calf serum (FCS), 20 ng/mL human GM-CSF (R&D Systems) and 10 ng/ml human IL-4 (R&D Systems) for 6 days (immature DC) (Chen et al., 2008). Human whole blood was obtained from healthy donors at the Taipei Blood Center of the Taiwan Blood Services Foundation, under a protocol (AS-IRB02-103202) approved by the IRB of the Clinical Center of the Department of Health, Taiwan. Written informed consent was obtained from all donors. For mouse bone marrow-derived DC (BMDC), bone marrow cells were isolated from femurs and tibias and cultured in RPMI 1640 complete medium supplemented with 10% (v/v) FCS, L-Glutamine, pen/strep and 40 ng/mL recombinant mouse GM-CSF (R&D Systems) for 9 days (Chen et al., 2008).

Virus Infection and Ligand Stimulation of Human moDC and Mouse BMDC

Human monocyte-derived dendritic cells (moDC) or mouse bone marrow derived dendritic cells (BMDC) were seeded at cell culture plates with a confluency of 80% in complete RPMI medium overnight. The cells were then washed with PBS and infected with VSV at the indicated MOI at 37°C in serum-free RPMI for 1 hr. The cells were then washed with PBS and cultured in the complete RPMI. For ligand stimulation, 5'ppp-dsRNA and LMW poly(I:C) were suspended in LyoVecTM transfection reagent (InvivoGen) for 15 min at room temperature according to the manufacturer's instruction. Mouse BMDC were seeded in 24-well plates at a density of 3×10^5 per well, and 25 μ L of 5'ppp-dsRNA/ LyoVecTM (0.01 μ g/ μ L) or LMW poly(I:C)/LyoVecTM transfection reagent (0.03 μ g/ μ L) was then transfected into BMDC, respectively. Supernatants and cells were harvested at 12 hr. IFN- β protein and *Ifnb*/*Ifna4* transcripts were measured by ELISA and real time qPCR, respectively.

RNA Isolation and mRNA Analysis

For mRNA detection, total RNA was extracted from GWAT lysate using TRIzol(Thermo Scientific). cDNA was generated from the total RNA by using ReverAid first strand cDNA Synthesis Kit (Cat. K1622, Thermo Scientific, Inc.). Quantitative RT-PCR was performed on a StepOnePlus 7 Real-Time PCR System with SYBR Green PCR Master Mix (Cat. BIO-98005, Thermo Scientific, Inc.).

Transfection and Luciferase Reporter Analysis

HEK293 cells were seeded in 24-well plates at a density of 3×10^5 per well and transfected using lipofectamineTM 2000 (Cat. 11668019, Thermo Scientific, Inc.) according to the manufacturer's instruction. Ten ng of pRT-TK Renilla luciferase reporter plasmid and 100 ng of firefly luciferase reporter plasmids were co-transfected with indicated plasmids. Luciferase activity was measured 24 h after transfection using the Dual-Glo Luciferase Assay System (Cat. E2920, Promega, Inc.).

Human NLRP12 Knockdown Experiment

Human moDC seeded in 12-well plates at a density of 5×10^5 per well were transfected with either 40 nM of pre-validated NLRP12 pool siRNA (sc-45388, Santa Cruz, CA) or a control siRNA using HiPerFect Transfection reagent (Cat. 301704, QIAGEN) for 48 h. Cells were then stimulated with VSV (MOI 1). Supernatants and cell lysates were at indicated time points for cytokine determination and immune blots analysis.

Co-immunoprecipitation and Ubiquitination Assays

Cells were lysed in 1% Triton X-100 isotonic buffer. Co-immunoprecipitations were performed using anti-V5-agarose gel, anti-HA-agarose beads and anti-Flag-M2 gel (all from Sigma) or 1 μ g antibody specific for TRIM5, RNF125, RIG-I, TRAF3, TRAF6 or IKK α with UltraLink Protein A/G beads (Pierce). For *in vitro* ubiquitination assays, mouse BMDC or HEK293 cells were lysed in 1% SDS isotonic buffer. Lysates were boiled for 15 min to remove any non-covalent interactions, followed by centrifugation for 10 min at 15,000 rpm. Supernatants were transferred to a new tube, and diluted with 1% Triton X-100 buffer for immunoprecipitation with anti-Flag M2 or 1 μ g of anti-RIG-I antibody and UltraLink Protein A/G beads. Immunocomplex was harvested and washed with 0.1% Triton X-100 isotonic buffer and resuspended with protein loading buffer.

Viral Genome Quantification and Determination of Virus Titer

Total RNA was isolated from homogenized cells or brain tissues using QIAamp RNA Mini Kit (Cat. 52904, QIAGEN, Inc) according to manufacturer's protocol. The RNA was reverse transcribed into cDNA and viral genome was quantified by SYBR green qPCR using VSV-specific primers. The relative VSV replication was obtained by setting the measured VSV expression in wild-type cells to 100%. The relative percentage of VSV expression in *Nlrp12*^{-/-} cells was calculated after comparing with wild-type cells (100%). The infective VSV particles from cells, serum or brains were determined by plaque assay in Vero cells, and denoted as plaque forming units per sample volume (pfu/mL) or per sample gram tissue (pfu/g).

Confocal Microscopy, Histopathology and Immunohistochemistry

Wild-type and *Nlrp12*^{-/-} BMDC (5×10^5) were seeded onto coverslips in a 12-well culture dish and were grown overnight before inoculation with VSV at an MOI 0.5 for 1 hr. Virus was removed and cells were replenished with RPMI medium containing FCS, and then were harvested at indicated time points. Cells were fixed with 4% paraformaldehyde (PFA), followed by permeabilization with 0.1% Triton-100. Cells were stained with anti-p65 (Cat. 8242, clone: D14E12; Cell Signaling, Inc.) and TRITC-conjugated anti-rabbit antibody (Cat: 111-225-003, Jackson ImmunoResearch, Inc.) and then were counterstained for nucleic acids and F-actin with DAPI and Alexa Fluor 488 Phalloidin (Cat: A12379, Thermo Scientific, Inc.), respectively. For the detection of NLRP12 in human DC, cells were seeded and infected with VSV at an MOI of 1 for 1 hr. Virus was then removed, and cells were replenished with RPMI medium containing FCS and then harvested at indicated time points. The infected cells were further incubated with mito-tracker® Deep Red FM at the final concentration of 500 nM for 30 min at 37°C. After incubation, cells were fixed in ice-cold 100% methanol for 15 min at -20°C and rinse three times with PBS for 5 min. The immunostaining was performed with anti-NLRP12 antibody (Cat. PA5-21027, ThermoFisher Inc.) and TRITC-conjugated anti-rabbit antibody. Cells were analyzed using confocal microscopy (Leica: TCS-SP5-MP-SMD) and images were analyzed with Leica LAS AF software. For histopathology and immunohistochemistry, brains were harvested and fixed in 10% neutral buffered formalin fixation solution. Fixed tissue was embedded in paraffin, sectioned and stained with hematoxylin and eosin (H&E). For immunohistochemistry, formalin-fixed paraffin-embedded tissues were cut into 5 μ m sections and slides were stained with anti-GFAP (Cat. 3670, clone: GA5; Cell Signaling, Inc.) and developed with chromogen diaminobenzidine (Cat. K3468, DAKO Inc.) and counterstained with Gills Haematoxylin.

Experimental VSV Infection Mouse Model and T Cell Adoptive Transfer

Four-week-old WT and *Nlrp12*^{-/-#2} littermate mice originating from the same breeders were cohoused for an additional 4-6 weeks to normalize the microbiome difference. Age- and sex-matched WT and *Nlrp12*^{-/-#2} littermate mice (8- to 10-week-old) from the above conditions were used for *in vivo* VSV infection (1×10^6 PFU). For the myeloid-specific *Nlrp12*-deficient mice, mice were cohoused for 4 weeks before the VSV infection experiment, and 8- to 10-week-old *Nlrp12*^{flox/flox} LysM-Cre⁺ mice and control littermates (*Nlrp12*^{flox/flox} LysM-Cre⁻) which were age- and sex-matched were used for the VSV infection experiment. For the germ free (GF) mice, age-, weight-, and sex-matched GF WT and *Nlrp12*^{-/-} mice were used for the VSV infection study. All of mice were anesthetized by injecting ketamine (150 mg/Kg) and rampone (30 mg/Kg) intraperitoneally, followed by administrating of 15 μ L volume of VSV (1×10^6 PFU) in the left nostril. Mice were monitored and body weight was recorded daily, and mice were sacrificed when displaying clinical morbidity or frank hind limb paralysis. The body weight of dead mice was included using the weight at the time of death in successive time points. In some experiments, blood and brain were harvested by 24 h post-infection to analyze the amount of IFN- β protein, transcript level of *ifn- β* gene and viral titer.

For the T cell adoptive transfer experiment, splenocytes and peripheral LNs were harvested from WT and *Nlrp12*^{-/-#2} mice, and bulk T cells were positively enriched using anti-Thy1.2 (CD90.2) magnetic beads (Miltenyi Biotec 130-049-101). *Rag2*-deficient male mice (10 to 12 week-old) were reconstituted with 2×10^7 T cells from WT or *Nlrp12*^{-/-#2} mice (8 week-old male mice). Two days later, mice were anesthetized by injecting ketamine and rampone intraperitoneally, followed by administrating of 15 μ L volume of VSV (1×10^6 PFU) in the left nostril. Mice were monitored and body weight was recorded daily. Mouse brains were harvested for IFN γ expression in T cells at day 3 and day 9 post-infection.

Isolation of Mononuclear Cells from the CNS and Flow Cytometry Analysis

Mononuclear cells (MNCs) were isolated from brains of VSV-infected mice as described (Chen et al., 2012). Briefly, PBS-perfused brains were minced into pieces, and the cell suspension was digested with HBSS buffer containing 0.05% (v/v) collagenase IV (Cat. C5138, Sigma Inc.) and 0.025 U/mL DNase I (Cat. D5025, Sigma Inc.) at room temperature for 30 min. Brain homogenates were passed through a cell strainer (40 μ m) and resuspended in 40% (w/v) Percoll-HBSS solution and overlaid onto 70% (w/v) Percoll-HBSS. Thirty % (w/v) Percoll-HBSS and HBSS were added prior to centrifugation at 200 g at 20°C for 40 min. After centrifugation, brain mononuclear cells (MNC) were recovered from the 70 - 40% interphase and washed with PBS to remove the residual Percoll. Isolated brain mononuclear cells were re-suspended in FACS buffer and stained as follows. To determine the expression of TNF and IFN- α in conventional myeloid DC (CD11b⁺CD11c⁺), MNC (5×10^5 /reaction) were incubated with a cocktail of surface marker antibodies including anti-CD11b-Alexa Fluor 647 (Cat. C101220, Biolegend Inc.) and anti-CD11c-BV421 (Cat. 5627852, BD Bioscience Inc.). The stained cells were then fixed and permeabilized with the CytoFix/perm solution (Cat. 554714, BD Bioscience Inc.), followed by washing with BD wash buffer and staining with anti-IFN- α -FITC (Cat. 22100-3, PBL Inc.) and anti-TNF-APC/Cy7 (Cat. 506344, Biolegend Inc.) for 30 min on ice in the dark. After washing with FACS buffer, cells were re-suspended in 1xPBS and analyzed with the Beckman Coulter Cytoflex. To determine RIG-I expression in DC and macrophages at

12 h post infections, MNC (5×10^5 /reaction) were incubated with a cocktail of surface marker antibodies including anti-CD11b-PE (Cat. 101208, BD Bioscience Inc.), anti-CD11c-BV421 (Cat. 5627852, BD Bioscience Inc.) and anti-F4/80-Alexa Fluor 647 (Cat. , Bio-Rad Inc.). Stained cells were then fixed and permeabilized with CytoFix/perm solution, followed by washing with BD wash buffer and staining with anti- RIG-I Alexa Fluor 488 (Cat. sc- 376845, Santa Cruz Inc.) for 30 min on ice in the dark. After washing with FACS buffer, cells were resuspended in 1xPBS and analyzed with the Beckman Coulter Cytotflex. To determine myeloid infiltrating cells at day 5 post infection, MNC were incubated with a cocktail of surface markers including CD3-APC/Cy7, CD11b-Alexa Fluor 647, Ly6G-FITC, Ly6C-PE and CD11c-BV421. To determine IFN γ expression in T cells at day 3 and day 9 post- infection, MNC (5×10^5 /reaction) were incubated with a cocktail of surface marker antibodies including anti-CD3-PE (Cat. 553064, BD Bioscience Inc.), anti-CD4-Alexa Fluor 647 (Cat. 553051, BD Bioscience Inc.) and anti-CD8-Alexa Fluor 488 (Cat. 100726, Biolegend Inc.). The stained cells were then fixed and permeabilized with CytoFix/perm solution, followed by washing with BD wash buffer and staining with anti-IFN γ -Alexa Fluor 700 (Cat. 505823, Biolegend Inc.). Stained cells were washed with FACS buffer and resuspended in PBS for analysis with the Beckman Coulter CytoFlex. All of the data were processed using FlowJo software (version 10, Treestar).

QUANTIFICATION AND STATISTICAL ANALYSIS

All data were presented as mean $\pm$ SEM and analyzed using GraphPad Prism software (Version 5.0). An unpaired, two-tailed Student's t test (for parametric data) or Mann-Whitney test (for nonparametric data) was used to determine the significance between two sets of data. Error bar represents mean $\pm$ SEM with * $p < 0.05$ and ** $p < 0.01$.

Cell Host & Microbe, Volume 25

Supplemental Information

NLRP12 Regulates Anti-viral RIG-I Activation via Interaction with TRIM25

Szu-Ting Chen, Liang Chen, Diego Shih-Chieh Lin, Sei-Yi Chen, Yen-Po Tsao, Haitao Guo, Fei-Ju Li, Wei-Ting Tseng, Jason W. Tam, Chih-Wei Chao, W. June Brickey, Ivan Dzhagalov, Moon-Jung Song, Hye-Ri Kang, Jae U. Jung, and Jenny P.-Y. Ting




Figure S1: Generation of *Nlrp12*^{-/- #2} mice, related to Figure 1, Figure 3 and STAR Methods. (A) A recognition sequence (crRNA, in the light blue arrow) in the single guide RNA (sgRNA) locating at upstream of the protospacer adjacent motif (PAM) of 5'-NGG-3' (red box) is in the *Nlrp12* exon 1.

(B) The donor vector contains the homologous sequence of *Nlrp12* exon 1 and 9 nucleotides encoding three stop codons (red color) with an artificially created *Ase* I restriction enzyme cutting site. (C) After introducing a double-strand break in the targeted sites of the *Nlrp12* allele by using the CRISPR/Cas9 system, the homologous donor vector was recombined and resulted in an inserted sequences with three stop codons and an *Ase* I restriction enzyme site (underline) in the exon 1. P1 indicates the PCR product using *Nlrp12* 3xstop primer sets. (D) Genotyping of homologous *Nlrp12^{stop}* allele (knock-in, *Nlrp12^{+/-#2}*) and heterozygous 3xstop codons at *Nlrp12* allele (*Nlrp12^{+/-#2}*) littermates. PCR products (P1) were digested with *Ase* I enzyme to determine the genotype by DNA size. Wild type and *Nlrp12^{-/-#2}* BMDC were transfected with (E) 5'ppp-dsRNA or (F) low molecular weight (LMW) poly(I:C). IFN- β protein and *Ifnb* transcripts were measured by ELISA and real time qPCR, respectively. (G) WT and *Nlrp12^{-/-#2}* BMDC were transfected with 5'ppp-dsRNA (0.625 μ g/ml), cell lysates were analyzed for pTBK1 and pIRF3.







A**B****C****D****E****F**

Figure S2: NLRP12 associates with TRIM25 and its expression is down-regulated by VSV infection, related to Figure 4 and Figure 5.

HEK293 cells were infected with VSV (MOI 1) following transfection of the HA-NLRP12 plasmid. Cell lysates were prepared and subjected to immunoprecipitation (IP) of endogenous (A) RIG-I, TRIM25 and TBK1, or (B) TRAF3, TRAF6 and IKK α with their respective antibodies followed by immunoblotting (IB) with anti-HA antibody to detect the association of these endogenous proteins with HA-NLRP12. (C) Human monocyte derived dendritic cells (moDCs) and (D) mouse BMDCs were infected with VSV and mRNAs were harvested at indicated time points. Human *NLRP12* and mouse *Nlrp12* expression was detected by qPCR analysis. *NLRP12* or *Nlrp12* expression level in the mock-infected cells was denoted as 100%, and the relative *NLRP12* or *Nlrp12* expression in the VSV-infected cells was expressed as a % of the level detected in mock-infected cells. Representative data were collected and expressed as mean $\pm$ s.e.m. from at least three independent experiments. Student's *t* test was performed, **P*<0.05; ***P*<0.01 for the *Nlrp12/NLRP12* expression in mock infected cells versus VSV-infected cells. (E) VSV-infected WT and *Nlrp12*^{-/-#2} BMDC were harvested and immunoblotted for RIG-I levels. (F) WT and *Nlrp12*^{-/-#2} BMDC were infected with VSV (MOI 0.5), and cell lysates were subjected to IP with antibody against RIG-I. Levels of Lys63-linked (upper) and Lys48-linked ubiquitin (lower) on RIG-I were measured by immunoblotting with antibodies against K63-Ub or K48-Ub.




Figure S3: Deficiency of *Nlrp12* increases RIG-I expression in dendritic cells and macrophages, related to Figure 6. (A) WT and *Nlrp12*^{-/-#2} mice were inoculated with VSV (1×10^6 pfu) intranasally, brains were harvested 12 hr post-infection to determine the population of myeloid dendritic cells which were detected with antibodies against CD11b and CD11c. Representative histogram of the percentage of CD11b⁺CD11c⁺ cells among brain mononuclear cells.

(B-C) Brains were harvested 12 hr post-infection, and RIG-I expression in dendritic cells (B) and macrophages (C) measured by FACS, displayed as a representative histogram and as composite data (right). (D-E) Same as (B-C) except RIG-I expression in splenic dendritic cells (D) and macrophages (E) was measured. Shaded histograms: isotype control, number: mean fluorescence intensity (MFI). Student's *t* test shows * $P < 0.05$.




Figure S4. Deficiency of *Nlrp12* does not alter the infiltration of immune cells into the brain, related to Figure 6. WT and *Nlrp12*^{-/-}#2 mice were inoculated with VSV (1×10^6 pfu) intranasally, and brains were harvested day 5 post-infection to determine the population of infiltrated immune cells. (A) Representative FACS data show the percentage of brain CD11b⁺CD11c⁺ cells among total mononuclear cells. (B) Percentages of brain monocytes (Ly6C^{hi}) and neutrophils (Ly6G⁺) were determined among CD11b⁺ cells. (C) Representative FACS data show the percentage of brain CD3⁺ T cells among total mononuclear cells (upper), and proportion of CD3⁺CD4⁺ or CD3⁺ CD8⁺ T cells (lower) among CD3⁺ T cells.




Figure S5. NLRP12 does not affect IFN- γ levels in T cells 3 days post VSV infection, related to Figure 7. WT and *Nlrp12*^{-/-#2} mice were inoculated with VSV (1×10^6 pfu) intranasally, and tissues were harvested day 3 post-infection to determine IFN- γ expression.

Representative FACS data show the proportion of CD3⁺, CD4⁺ or CD3⁺, CD8⁺ T cells in (A) infected brain and (B) draining submandibular LN under CD3⁺ T cells gating condition. IFN- γ levels in brain CD4⁺ T cells (C), CD8⁺ T cells (D), submandibular LN CD4⁺ T cells (E) and submandibular LN CD4⁺ T cells (F) measured by FACS are displayed as representative histograms. Shaded histograms: isotype control; number: mean fluorescence intensity. The composite data at the right side of each representative histogram were collected and expressed as mean $\pm$ s.e.m. from at least five mice for each experimental group.




Figure 6S. NLRP12 does not affect IFN- γ levels in T cells 9 days post VSV infection, related to Figure 7. WT and *Nlrp12*^{-/-#2} mice were inoculated with VSV (1×10^6 pfu) intranasally, and tissues were harvested day 9 post-infection to determine IFN- γ expression.

Representative FACS data show the proportion of CD3⁺, CD4⁺ or CD3⁺, CD8⁺ T cells in the (A) infected tissue: brain and (B) draining lymph node: submandibular LN among CD3⁺ T cells. IFN- γ levels in brain CD4⁺ T cells (C), CD8⁺ T cells (D), submandibular LN CD4⁺ T cells (E) and submandibular LN CD4⁺ T cells (F) measured by FACS are displayed as representative histograms. Shaded histograms: isotype control; number: mean fluorescence intensity. The composite data at the right side of each representative histogram were collected and expressed as mean $\pm$ s.e.m. from at least five mice for each experimental group. at least five mice for each experimental group.




Figure 7S. *Nlrp12*-deficiency in T cells does not affect IFN- γ expression during VSV infection, related to Figure 7. (A) Reconstitution of *Rag2*^{-/-} mice with T cells followed by VSV inoculation. (B) At day 9 post-infection, brain MNC were assayed for CD4⁺ and CD8⁺ T cells and (C) the levels of IFN- γ by brain CD4⁺ and CD8⁺ T cells as determined by FACS analysis and displayed as representative histograms. Shaded histograms: isotype control; number: mean fluorescence intensity.